Sharma v. Secretary of Health and Human Services

In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 16-834V
Filed: May 15, 2020

* * * * * * * * * * * * * * *
P.S., * To Be Published
*
Petitioner, *
v. * Dismissal; Ruling on the Record;
* Hepatitis B Vaccine; Undifferentiated
SECRETARY OF HEALTH * Connective Tissue Disease (“UCTD”);
AND HUMAN SERVICES, * Ankylosing Spondylitis; Autoimmune or
* Atrophic Gastritis; Significant
Respondent. * Aggravation
* * * * * * * * * * * * * * *

Richard Moeller, Esq., Moore, Heffernan, et al., Sioux City, IA, for petitioner.
Voris Johnson, Esq., U.S. Department of Justice, Washington, DC, for respondent.

RULING ON THE RECORD AND DECISION DISMISSING PETITION1

Roth, Special Master:

On July 14, 2016, P.S. (“petitioner”) filed a petition for compensation pursuant to the
National Vaccine Injury Compensation Program,2 alleging that he developed undifferentiated
connective tissue disease (“UCTD”), autoimmune or atrophic gastritis, and other injuries, which
were either caused or significantly aggravated by hepatitis B vaccinations he received on August
14, 2013, December 17, 2013, and May 16, 2014. See Petition (“Pet.”), ECF No. 1. Petitioner has
filed a Motion for Ruling on the Record. The undersigned finds that petitioner has failed to carry
his burden of showing that hepatitis B vaccines caused his UCTD, autoimmune or atrophic
gastritis, or any other injuries. The petition is accordingly dismissed.

1
This Decision has been formally designated “to be published,” which means it will be posted on the Court
of Federal Claims’ website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, 116
Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501 note (2006)). This means the Decision will be
available to anyone with access to the internet. However, the parties may object to the Decision’s
inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party
has fourteen days within which to request redaction “of any information furnished by that party: (1) that is
a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes
medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of
privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public. Id.
2
National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease
of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa
(2012).
 I. Background

A. Procedural History

The petition was filed on July 14, 2016, along with several medical records. See Petition,
ECF No. 1; Pet. Ex. 1-4, ECF No. 3. On July 15, 2016, petitioner filed several articles of medical
literature related to the hepatitis B vaccine and UCTD. See Pet. Ex. 5-10, ECF No. 4.

An initial status conference was held on August 24, 2016. Scheduling Order, ECF No. 9.
Respondent had not yet had an opportunity to review petitioner’s records and requested time to
determine whether there were any outstanding medical records. Id. Petitioner filed additional
medical records through September of 2016. See Pet. Ex. 11, ECF No. 10; Pet. Ex. 11A, ECF No.
11; Pet. Ex. 12, ECF No. 16; Pet. Ex. 13, ECF No. 17.

On November 17, 2016, respondent filed his Rule 4(c) Report (“Resp. Rpt.”), stating the
case was not appropriate for compensation. Resp. Rpt., ECF No. 20. Respondent raised several
issues including petitioner’s lack of a definitive diagnosis for his alleged injury, stating it was the
petitioner’s burden “to demonstrate that he actually suffers from the injury alleged, UCTD.” Id. at
17. Additionally, respondent stated “virtually every specialist [petitioner] saw expressed
skepticism that the hep B (sic) vaccine was the cause of his symptoms.” Id. Finally, respondent
noted two of petitioner’s treating physicians were concerned that petitioner’s symptoms related to
his mental health and offered referrals to mental health professionals, which petitioner refused. Id.
at 7-8, 13.

A status conference was held on January 11, 2017 to discuss the issues raised by
respondent’s Rule 4(c) Report. Scheduling Order at 1, ECF No. 21. Petitioner’s counsel advised
that petitioner was suffering from UCTD as alleged in the petition and planned to have an expert
review petitioner’s medical records. Id. Respondent’s counsel raised reasonable basis in the filing
of the petition. Id.

Petitioner was ordered to file an expert report or a status report indicating how he intended
to proceed by March 13, 2017. Id. Petitioner requested and received five extensions of time. See
ECF Nos. 22, 24, 26, 27, 28. On December 8, 2017, petitioner filed a status report requesting a
status conference. Pet. S.R., ECF No. 29. A status conference was held on December 19, 2017 at
which time petitioner’s claim was again discussed, specifically petitioner’s lack of a definitive
diagnosis for his alleged injuries, that all objective testing was normal, and there was no temporal
relationship between petitioner’s receipt of the hepatitis B vaccines and any injury. Scheduling
Order at 1, ECF No. 30. Petitioner’s counsel advised he had done all he could do to secure an
expert report but had been unsuccessful, and that he planned to withdraw as counsel. Id. After
further discussion, an Order was issued for counsel to file Motions for Attorneys’ Fees and Costs
and to Withdraw as counsel by February 2, 2018. Id. at 2.

Petitioner filed additional medical records on February 1, 2018. Pet. Ex. 14-15, ECF Nos.
31-32. Petitioner’s counsel filed Motions for Interim Fees and Costs and to Withdraw as counsel
on February 2, 2018. ECF Nos. 33-34. Respondent filed his response to petitioner’s Motion for
Attorney’s Fees and Costs on February 13, 2018 and petitioner filed a reply on March 20, 2018.

2
See ECF Nos. 36, 41. Based on the filings, the undersigned deferred ruling on the Motion for
Attorney’s Fees and Costs until after entitlement was decided and granted the Motion to Withdraw
as counsel. See Order, ECF No. 42; Order, ECF No. 43. The docket reflected the petitioner as pro
se.

On May 7, 2018, petitioner’s current counsel electronically filed a Motion to Substitute
Attorney in place of petitioner as pro se. ECF No. 45. An Order was issued on May 9, 2018
instructing the pro se petitioner to file his motion via paper filing by May 22, 2018. See Order,
ECF No. 46. Petitioner’s electronically filed Motion to Substitute Attorney was stricken See id.
On May 18, 2018, petitioner properly filed a Motion to Substitute Attorney substituting Richard
Moeller as petitioner’s counsel. ECF No. 47.

Petitioner filed additional medical records through July 2, 2018. See Pet. Ex. 28-30, ECF
No. 49; Pet. Ex. 31, ECF No. 50.

The first status conference with Mr. Moeller as counsel was held on July 24, 2018. See
Scheduling Order at 1, ECF No. 52. Mr. Moeller advised that he had secured an expert who was
willing to review the medical records and advise whether a claim could be supported. Id.
Petitioner’s counsel was reminded that reasonable basis had been raised by respondent and
reimbursement of attorney’s fees and costs was not guaranteed. Petitioner’s counsel was further
reminded that any expert should rely on the contemporaneous medical records, which are assumed
to be accurate and complete. See id. Petitioner was ordered to file an expert report or a status report
by October 22, 2018. Id. at 2, ECF No. 52. On October 22, 2018, petitioner filed a status report
advising that he did not have an expert report. ECF No. 53.

Another status conference was held on December 6, 2018. See Scheduling Order at 1, ECF
No. 54. Petitioner’s counsel stated that neither he nor his client were financially capable of paying
the costs for an expert and petitioner believed the Vaccine Program should retain an expert for
him. Id. As a seasoned attorney in the Program, Mr. Moeller was reminded that it was petitioner’s
burden to prove his case and retain an expert when necessary. Id. The various ways to exit the
Program were discussed and 60 days for counsel to discuss the options with petitioner was ordered.
Id. at 2.

On February 4, 2019, petitioner filed additional medical records and a status report. Pet.
Ex. 32, ECF No. 55; ECF No. 56. In his status report, petitioner requested a ruling on the record
that should include a “thorough review of the medical records filed in this matter, as well as injuries
claimed to have been sustained following the receipt of the allegedly causal vaccinations, and
petitioner’s claims of ongoing injuries and damages….” ECF No. 56

Petitioner was ordered to file his Motion for Ruling on the Record by April 5, 2019. See
Non-PDF Order, issued Feb. 4, 2019.

On February 13, 2019, the petitioner made several telephone calls to chambers. Petitioner
was informed by my law clerk that all communications were to be made through his attorney of
record. See Scheduling Order at 1, ECF No. 57.

3
 A status conference was held on February 27, 2019. See Scheduling Order at 1, ECF No.
57. Just prior to the scheduled conference call, Mr. Moeller emailed chambers to inform the
undersigned that petitioner had questions he wanted answered by the Special Master. Id. At the
status conference, petitioner’s counsel read petitioner’s questions which reflected his discontent
with the Vaccine Program and the Program’s refusal to hire an expert for him or advance the costs
for an expert. Id. As an experienced attorney in the program, petitioner’s counsel was advised that
he was well-equipped to provide petitioner with the answers to the questions he posed and the
explanations for same. Id. at 1-2.

On April 3, 2019, petitioner filed updated medical records. Pet. Ex. 33, ECF No. 58. On
April 5, 2019, petitioner filed an unopposed Motion for Extension of Time to file a Motion for
Ruling on the Record. ECF No. 58.

Petitioner filed updated medical records and a Motion for Ruling on the Record on April
12, 2019. Pet Ex. 34-44, ECF No. 60; Motion for Ruling on the Record, ECF No. 61. Respondent
filed a response on April 22, 2019. Response, ECF No. 62.

On May 3, 2019, petitioner filed a Motion for Extension of Time to file a reply. ECF No.
63. Petitioner further requested “that the special master suspend her consideration and ruling on
petitioner’s motion for ruling on the record” to allow petitioner time to submit his medical records
to a potential expert, Dr. Shoenfeld, for review.” Id. at 1. Respondent filed a response on May 8,
2019, objecting to petitioner’s Motion stating, “Petitioner has had over two-and-a-half years since
respondent filed his Rule 4(c) Report to have Dr. Shoenfeld (or some other expert) offer a causal
opinion in support of his claim.” ECF No. 64 at 3.

The undersigned granted the Motion for Extension of Time, ordering petitioner to file an
expert report by June 19, 2019 and a Motion to withdraw his Motion for Ruling on the Record by
June 4, 2019. See Order at 2, ECF No. 65.

Petitioner filed a status report on June 13, 2019, advising that he would not be withdrawing
his original Motion for Ruling on the Record and would not be filing an expert report from Dr.
Shoenfeld. ECF No. 67.

This matter is now ripe for ruling.

B. Petitioner’s Health Prior to the Hepatitis B Vaccines

The earliest medical record filed by petitioner begins with an examination on February 21,
2011. At that time, petitioner complained of an anal fistula3 that had “been going on for some
time.” A colonoscopy was unremarkable. Pet. Ex. 2 at 3-7.

3
An anal fistula is “a cutaneous fistula opening on the body surface near the anus; it may or may not
communicate with the rectum.” Anal fistula, DORLAND’S ILLUSTRATED MEDICAL DICTIONARY 704 (32nd
ed. 2012) [hereinafter “DORLAND’S”].

4
 The next record is a little over a year later, on March 22, 2012, when petitioner presented
for abdominal ultrasound, which was normal. Pet. Ex. 1 at 12. The record does not contain a
reason for why an abdominal ultrasound was ordered.

On May 16, 2012, petitioner presented to Dr. Sami, a dermatologist at the Kirklin Clinic,
with a history of itching for the past year and hair loss at the root for the past 15 months. Pet. Ex.
1 at 14; see also Pet. Ex. 3 at 147-49. Upon examination, petitioner had diffuse thinning of the hair
over the scalp, mild erythema4 and scaling, and scattered papules and pustules. Id. at 15. He was
diagnosed with cutis xerosis5, urticaria6, seborrheic dermatitis, male pattern hair loss, and
folliculitis. Id. at 16. Triamcinolone ointment,7 Allegra, Atarax,8 medicated shampoo, Rogaine,
and panoxyl bar soap were prescribed. Id.

On June 14, 2012, petitioner presented to Dr. Dasher, a gastroenterologist at the Kirklin
Clinic, with multiple complaints, including upper abdominal pain, some diarrhea, and past rectal
bleeding which improved with a better diet. Pet. Ex. 1 at 18; see also Pet. Ex. 3 at 143-46. Petitioner
reported that he had a complete colon examination 15 months ago, with no major findings. Id.
Petitioner advised that he had pruritus9 and perianal itching. Id. He was worried about liver disease.
Id. Upon examination, petitioner had two perianal papillary lesions; it was noted that the lesions
seemed to be larger than described during the prior colonoscopy. Id. at 20, 21. An
esophagogastroduodenoscopy was recommended to determine the cause of petitioner’s abdominal
pain, but petitioner declined. Id. at 21.

On July 30, 2013, petitioner presented to the emergency department at the University of
Alabama at Birmingham Medical Center (“UAB”) with rectal bleeding and pain ongoing for
several weeks. Pet. Ex. 1 at 161, 169. It was noted that petitioner previously saw Dr. Dasher in
4
Erythema means “redness of the skin.” Erythema, DORLAND’S at 636.
5
Cutis xerosis is also known as “asteatotic eczema.” Xerosis cutis, DORLAND’S at 2056. It is “a condition
resulting from excessive dehydration of the skin, characterized by erythema, dry scaling, fine cracking, and
pruritis; it occurs chiefly during cold weather when low humidity in heated rooms causes excessive water
loss from the stratum corneum.” Asteatotic eczema, id. at 586.
6
Urticaria is “a vascular reaction in the upper dermis, usually transient, consisting of localized edema
caused by dilatation and increased capillary permeability with wheals.” Urticaria, DORLAND’S at 1981.
7
Triamcinolone is a corticosteroid used to reduce inflammation. It can be applied topically as a cream to
treat eczema and other forms of dermatitis. Triamcinolone Acetonide– Drug Summary, PDR.NET,
https://www.pdr.net/drug-summary/Triamcinolone-Acetonide-Cream-triamcinolone-acetonide-
1503.2069#4 (last visited Mar. 27, 2020).
8
Atarax is the brand name for hydroxyzine hydrochloride, an antihistamine used to treat allergic conditions
like chronic urticaria, atopic dermatitis, or contact dermatitis. Hydroxyzine hydrochloride – Drug Summary,
PDR.NET, https://www.pdr.net/drug-summary/Hydroxyzine-Hydrochloride-Syrup-hydroxyzine-
hydrochloride-740.8332 (last visited Mar. 27, 2020).
9
Pruritis is “an unpleasant cutaneous sensation that provokes the desire to rub or scratch the skin to obtain
relief.” Pruritis, DORLAND’S at 1516.

5
 June of 2012, and at that time was noted to have a 5-6 mm nodule. Id. at 169. Routine labs were
unremarkable. Id. at 171. Petitioner was prescribed Percocet 10 and Colace, a stool softener, and
discharged. Id. Dr. Heslin, a surgical oncologist, recommended that petitioner return for outpatient
follow-up. Id.

On August 1, 2013, petitioner presented to the emergency department at UAB, complaining
that his rectal pain and bleeding had not resolved. Pet. Ex. 1 at 197. He did not want to eat or use
the restroom due to the pain. Id. Petitioner was seen by Dr. Foster, who noted that petitioner had
been referred to surgical oncology for evaluation and had an appointment for August 8. 11 Id. at
203. He presented to the ER with increasing abdominal pain with defecation. Id. An abdominal
CT was negative for metastatic disease but did show thickening and irregularity of the anorectal
region. Id. at 209; see also Pet. Ex. 12 at 4. An underlying mass could not be excluded. Id.
Petitioner was prescribed lactulose12 and Miralax, a stool softener, and discharged. Id. at 205.

C. Petitioner’s Health After the First Hepatitis B Vaccine

Petitioner received three hepatitis B vaccinations on August 14, 2013; December 17, 2013;
and May 16, 2014, respectively.

On August 14, 2013, petitioner presented to Dr. Landen, a family medicine physician at
the Kirklin Clinic, for follow up of his ER visit for rectal pain. Pet. Ex. 3 at 139; see also Pet. Ex.
13 at 9-12. Dr. Landen noted the prior history of rectal pain “over the last couple of years.” Id.
Also noted were the results of petitioner’s CT scan in the ER with questionable mass; petitioner
reported that he had seen the surgical oncologist and was scheduled for a repeat colonoscopy and
exam under anesthesia with possible biopsy. Id. Dr. Landen wrote, the patient was “very concerned
and has a lot of questions.” Id. at 141. Dr. Landen referred petitioner to a gastroenterologist and
advised that he needed to receive the hepatitis B vaccine series. Id. Petitioner’s ongoing conditions
were listed as rectal mass, vitamin D deficiency, eczema, and hypertriglyceridemia, among other
issues.13 Id. at 140. Dr. Landen noted petitioner wanted to come back for the hepatitis B vaccine
“on Friday.”14 Pet. Ex. 3 at 142. Other records document petitioner’s receipt of the first hepatitis
B vaccine at the August 14, 2013 visit. Pet. Ex. 1 at 177.

10
Percocet is the brand name for a combination of acetaminophen and oxycodone. It is a strong opiate agonist
used to treat acute, severe pain. Acetaminophen/oxycodone – Drug Summary, PDR.NET,
https://www.pdr.net/drug-summary/Percocet-acetaminophen-oxycodone-2483.1051 (last visited Mar. 27,
2020).
11
The record for the August 8 visit to surgical oncology was not filed.
12
Lactulose is a laxative used to treat constipation. Lactulose – Drug Summary, PDR.NET,
https://www.pdr.net/drug-summary/Constulose-lactulose-1544 (last visited Mar. 27, 2020).
13
Hypertriglyceridemia means “excessive triglycerides in the blood.” Hypertriglyceridemia, DORLAND’S
at 886.
14
“Friday” would be August 16, 2013. There are no records of a medical visit on this date.

6
 On August 20, 2013, petitioner presented to Dr. Heslin, a surgical oncologist at Kirklin
Clinic, for a proctoscopy.15 Pet. Ex. 1 at 575-76. Dr. Heslin performed incision and drainage of the
perianal fistula under anesthesia and biopsy. Id. Upon discharge, petitioner was prescribed
Dilaudid16 and Colace; he was also given instructions for sitz baths as well as ways to avoid
constipation. Id. at 578.

On September 5, 2013, petitioner returned to Dr. Heslin for post-operative care. Pet. Ex. 3
at 137. Biopsy results showed “moderate to severe acute and chronic inflammation with
ulceration” compatible with a fistula. Id. No granulomas were identified. Id. Petitioner reported
less pain and doing well. Id. at 138. Dr. Heslin advised petitioner to schedule a follow-up visit with
Dr. Landen. Id.

There were no medical records filed of any medical visits between September 5, 2013 and
December 17, 2013, and no complaints of any adverse events following the August 14, 2013
hepatitis B vaccine.

D. Petitioner’s Health After the Second Hepatitis B Vaccine

On December 17, 2013, petitioner received a second hepatitis B vaccine. Pet. Ex. 1 at 177.
There were no medical records filed between December 17, 2013 and May 16, 2014, for any
medical care generally or specifically related to any complications or adverse events associated
with the December 17, 2013 hepatitis B vaccination.

E. Petitioner’s Health After the Third Hepatitis B Vaccine

On May 16, 2014, petitioner received a third hepatitis B vaccine. Pet. Ex. 1 at 176. There
were no records filed for any medical care between May 16, 2014 and February 19, 2015.

On February 19, 2015, petitioner presented to Dr. Salser at Kirklin Clinic. Pet. Ex. 3 at 131.
He reported developing a cough and sore throat on February 3, 2015. Id. The cough was lingering.
Id. He also complained of left-sided abdominal pain that started a week ago but had improved over
the past three or four days. Id. He requested imaging to evaluate it. Id. Dr. Salser documented
petitioner’s history of perianal fistula, eczema, vitamin D deficiency, and hypertriglyceridemia,
among other issues. Id. at 131-32. Abdominal ultrasound and liver function tests were ordered. Id.
at 135. Petitioner was advised to use Mucinex DM for his cough. Id. at 136.

Three months later, on May 18, 2015, petitioner returned to Kirklin Clinic and was
examined by Dr. Davuluri for chief complaints of mid-back and neck pain. Pet. Ex. 3 at 126. He

15
A proctoscopy is the “inspection of the rectum with a proctoscope” Proctoscopy, DORLAND’S at 1498. A
proctoscope is a “speculum or tubular instrument with appropriate illumination for inspecting the rectum.”
Proctoscope, id. at 1498.
16
Dilaudid is the brand name for hydromorphone hydrochloride. It is a strong opiate agonist used to treat
acute or chronic moderate to severe pain. Hydromorphone hydrochloride – Drug Summary, PDR.NET,
https://www.pdr.net/drug-summary/Dilaudid-Liquid-and-Tablets-hydromorphone-hydrochloride-489 (last
visited Mar. 27, 2020).

7
reported receiving a hepatitis B vaccine a year prior in May of 2014, left knee pain beginning in
June of 2014, and a cold in February of 2015 with bloody sputum and ear “fluttering” that lasted
10 days, which was unusual for him as his colds normally lasted one to three days. Id. He then
developed left-sided neck, upper back, and spine pain at the beginning of May 2015 which was
initially severe but lessened when he started swimming. Id. Currently, his neck and back pain
were a 3/10, worse in the morning when he got up and easing as the day went on. Id. He had no
radiculopathy. Id. “Last night,” he felt transient electric shocks while asleep and when he moved
his extremities, he felt his head was “shivering,” and he could not sleep. Id. Dr. Davuluri wrote:

[Petitioner’s] main concern is that he assumes all these above event (sic) which
happened are related to adverse reaction caused from his last hepatitisvaccination.
(sic) he informs me that he reviewed a number [of] articles which relayed similar
symptoms [after] the vaccination he is worried about “weakened immune system,
transvermyelitis, (sic) MS17, requests blood test, MRI of spine, brain, knee” to avoid
worsening injury to his spine or worsening assumed side effects from vaccination[.]

Id. at 127. On the day of his visit, he reported a cracking noise in his neck when he turned to the
right, but no neck pain, no upper or lower extremity weakness, no trouble walking, no bowel or
bladder issues, no sensory abnormalities, no visual issues, and no hearing loss. Id. Dr. Davuluri
suggested that petitioner use topical anti-inflammatories, Advil, and heating pads for his neck pain.
Id. at 130. She wrote:

I am unable to relate his symptoms/clinical conditions as an adverse effect to
hepatitis B vaccination, infact (sic) I am unaware of this at this time. But based on
his symptoms and normal neurological exam there is no indication for MS or
Transever (sic) myelitis. I am not aware of what caused the transient electric shock
like symptoms last night. At this time I recommend no further tests or imaging
unless symptoms become more frequent/worsening/progressing. I encouraged him
to keep a log of his symptoms and if they become frequent or recurrent to inform
us. He seem (sic) dissatisfied with the answer today, I suggested that he discuss
with his PCP Dr Salser about this.

Id.

On May 23, 2015, petitioner presented to UAB Emergency Department with paresthesias.18
Pet. Ex. 1 at 336-41, 349-50. Petitioner described his symptoms as “pain in back, left eyelid

17
Transverse myelitis is an inflammation of the spinal cord in which the functional effect of the lesions
spans the width of the entire cord at a given level. Transverse Myelitis, DORLAND’S at 1201; myelitis, id.
Multiple sclerosis is “a disease in which there are foci of demyelination throughout the white matter of the
central nervous system, sometimes extending into the gray matter; symptoms usually include weakness,
incoordination, paresthesias, speech disturbances, and visual complaints. The course of the disease is
usually prolonged, so that the term multiple also refers to remissions and relapses that occur over a period
of many years…the etiology is unknown.” Multiple Sclerosis, id .at 1653.
18
Paresthesia means “an abnormal touch sensation, such as burning, prickling, or formication, often in the
absence of an external stimulus” Paresthesia, DORLAND’S at 1362.

8
flickering, hearing crackling when he turn (sic) neck, ‘shock’ type sensations at times in
extremities at night, spots of itching on legs, left knee pain, numbness in arms and fifth...finger at
times when he awakens.” Id. at 342. He claimed onset of these symptoms after receiving the
hepatitis B vaccine. Id. He stated he came to the Emergency Department because his primary care
physician was “unable or unwilling to further evaluate his symptoms.” Id. at 348. The physician,
Dr. Gilford, listed the differential diagnosis as “Peripheral neuropathy vs MS vs other neurological
condition vs anxiety.” Id. at 349. A “[p]hysical exam reveal[ed] no significant findings.” A CT
scan was normal. Id. at 349, 350, 354-55. He was instructed to follow-up with a neurologist. Id. at
350.

On May 29, 2015, petitioner returned to Dr. Salser, reporting neck pain and bilateral arm
“shocks” and numbness. Pet. Ex. 3 at 120. He stated his neck pain began on the left side in May
of 2014. Id. He reported on May 16, 2014, he had a “paralytic attack” with inability to get out of
bed. Id. On May 17, 2014, he “began to have [an] electric shock sensation followed by numbness
in bilateral hands and arms.” Id. at 121. He reported a recent URI that lasted for 10 days, which he
claimed was due to the vaccine. Pet. Ex. 13 at 24-25. Dr. Salser wrote petitioner was “convinced”
of the connection between the vaccines and all of his musculoskeletal problems and neurological
complaints and was becoming frustrated at the delay of “necessary tests” to diagnose him. Id. at
29. Dr. Salser described petitioner’s behavior as “Agitated, Belligerent, Compulsive, Pressured
speech” and noted “Abnormal/Psychotic thoughts: Ideas of influence, Misinterpretations,
Obsessions.” Id. at 27.

On June 2, 2015, petitioner presented to Dr. Agnihotri, a neurologist, with concerns he had
transverse myelitis connected to the hepatitis B vaccine. Pet. Ex. 13 at 32. He brought a written
chronology of all his symptoms. Id. He complained of convulsions and electrical shock sensations
while sleeping, weakness, numbness and stiffness in both arms, a “cracking noise” when moving
his neck, and neck pain while sleeping. Id. at 33-36. His neurological exam was normal. Id. at 37-
38. Petitioner reported that his review of the literature suggested he had suffered adverse effects
from the vaccine; Dr. Agnihotri wrote he seems “very convinced” the vaccine was the cause of his
symptoms. Id. at 38. She further noted petitioner’s “symptoms localize poorly.” She did not believe
they were related to the hepatitis B vaccine. Id. at 38.

Petitioner had an MRI of his cervical spine with and without contrast on June 11, 2015,
which revealed “[m]ild multilevel degenerative changes of the cervical spine, without evidence of
spinal cord compression or significant neural foraminal narrowing” and “[l]eft paracentral disc
extrusion contacting the spinal cord at the T1-2 level, incompletely evaluated in this cervical spine
exam.” Pet. Ex. 12 at 9-10. An MRI of the thoracic spine on June 23, 2015 revealed “[l]eft
paracentral protrusion at T1-2 with cephalad extruded component deforming the left anterior cord.
No cord signal abnormalities appreciated at this time.” Id. at 11-12.

On June 26, 2015, petitioner returned to Dr. Salser for generalized joint and nerve pain.
Pet. Ex. 13 at 42. Petitioner reported pain and a “cracklin (sic)” noise in his neck, numbness and
weakness of both arms, shoulder pain that “[c]omes and goes,” left knee pain and popping causing
discomfort and instability, fatigue in the morning, and shortness of breath. Id. at 42-43. He was
still working out, walking, and running daily, despite his knee pain. Id. at 42. Dr. Salser ordered a

9
blood panel, including an intrinsic factor19 antibody test, which was negative. Id. at 46-47.
Petitioner was diagnosed with fatigue and a vitamin B12 deficiency. Id. at 46.

On June 30, 2015, petitioner returned to Dr. Agnihotri. Pet. Ex. 13 at 49; see also Pet. Ex.
3 at 102. His paresthesias had improved significantly since taking vitamin B12 and D supplements.
Id. He continued to be concerned about the etiology of his B12 deficiency, complained he was still
fatigued in the morning with diffuse joint pain, and voiced concerns that his vitamin B12
deficiency was an indication of MS. Id. He wanted to know “if there’s anything else that could be
studied,” due to “significant concern about his symptoms.” Id. at 49-50. Dr. Agnihotri wrote
petitioner has “significant focus and concern on his symptoms” and had “been reading a lot about
them and has many questions and theories, including the association with his last HBV vaccine.”
Id. at 52. Dr. Agnihotri wrote most symptoms could be explained by his vitamin B12 deficiency
and “reinforced that there’s no evidence of MS since this is one of his main concerns.” Id. at 52-
53. Dr. Agnihotri suggested testing petitioner for pernicious anemia.20 Id. at 52. She further
indicated that somatization21 and somatoform22 disorders should be considered, along with stress
and anxiety, as a possible cause of petitioner’s symptoms. Id.

Petitioner underwent MRI of his left knee on July 6, 2015, which showed “[f]ocal patellar
chondromalacia overlying the mid sagittal ridge” but was otherwise unremarkable. Pet. Ex. 12 at
13-14.

On July 8, 2015, petitioner presented to Drs. Weber and Black at UAB’s gastrointestinal
clinic. He complained of “ongoing fatigue and subjective weakness in his arms,” but denied
memory problems, confusion, gait abnormalities, diarrhea, constipation, bloating, or abdominal
pain. Pet. Ex. 13 at 55. He was a vegetarian and drank milk. Id. The record documents, “His B12
deficiency is due to pernicious anemia (autoimmune23 gastritis24) – low B12 level combined with

19
Intrinsic factor is a mucoprotein required for adequate absorption of vitamin B12; a deficiency in intrinsic
factor results in pernicious anemia. Intrinsic factor (IF), STEDMAN’S MEDICAL DICTIONARY 317050,
accessed via westlaw.com (last visited May 7, 2020) [hereinafter “STEDMAN’S”].
20
Pernicious anemia is a chronic progressive anemia of older adults, occurring more frequently during the
fifth and later decades, due to failure of absorption of vitamin B12, usually resulting from a defect of the
stomach and associated with lack of secretion of “intrinsic factor.” It is characterized by numbness and
tingling, weakness, and a sore smooth tongue, as well as dyspnea after slight exertion, faintness, pallor of
the skin, anorexia, diarrhea, weight loss, and fever. Pernicious anemia, STEDMAN’S at 36730.

Somatization is “the conversion of mental experiences or states into bodily symptoms.” Somatization,
21

DORLAND’S at 1705.
22
Somatoform is a term used to describe “physical symptoms that cannot be attributed to organic disease
and appear to be of psychic origin.” Somatoform, DORLAND’S at 1705.
23
Autoimmune means “characterized by a specific humoral or cell-mediated immune response against
constituents of the body’s own tissues (self antigens or autoantigens).” Autoimmune, DORLAND’S at 178.
24
Gastritis is an “inflammation of the stomach.” Gastritis, DORLAND’S at 754.

10
an elevated parietal cell antibody. We explained to him that negative intrinsic factor antibody can
be seen with pernicious anemia. Since starting B12 supplementation his neurologic symptoms have
improved.” Id. at 58. Petitioner was instructed to continue supplementing his diet with vitamin
B12. Id.

On July 13, 2015, petitioner presented to Dr. Salser with complaints of worsening elbow
joint crepitus,25 polyarthralgia,26 pain in his thumb when moving his right hand, chronic knee pain,
and crepitus of the left knee. Pet. Ex. 13 at 59; 63. Petitioner’s fatigue had improved on vitamin D
supplements. Id. at 59. Dr. Salser planned to recheck inflammatory labs and referred petitioner to
a rheumatologist. Id. at 63.

On July 22, 2015, petitioner returned to Dr. Weber, reporting ongoing atrophic gastritis,27
multiple myalgias, and arthralgia. Pet. Ex. 1 at 44. Dr. Weber concluded his symptoms were likely
due to pernicious anemia rather than the hepatitis B vaccine. Id. at 47.

On July 23, 2015, petitioner presented to Dr. Smith at Highlands Rheumatology
complaining of body fatigue, knee pain, and elbow pain caused by hepatitis B vaccines. Pet Ex. 1
at 34-35; Pet. Ex. 3 at 84-85. Irritable bowel syndrome was ruled out. Dr. Smith could not find any
evidence of inflammatory arthritis. Id. at 35, 39. An MRI confirmed mild osteoarthritis.28 Id. at 39.
Dr. Smith did not see a connection between the hepatitis B vaccine and osteoarthritis. Id. at 39.
Petitioner expressed concerns for his symptoms becoming disabling. Id. at 40.

On July 24, 2015, petitioner underwent colonoscopy that found hemorrhoids29 but was
otherwise normal. Pet. Ex. 1 at 25, 27.

On July 29, 2015, petitioner returned to Dr. Weber with complaints of intermittent rectal
bleeding, diarrhea, fever, and inflammatory signs. Pet. Ex. 1 at 29. Petitioner advised of his
multiple rheumatological complaints, stating the rheumatologist did not think a rheumatological

25
Joint crepitus is “the grating sensation caused by the rubbing together of the dry synovial surfaces of
joints.” Joint crepitus, DORLAND’S at 424.
26
Polyarthralgia is pain in many different joints. Polyarthralgia, DORLAND’S at 1464; arthralgia, id. at
154.
27
Atrophic gastritis is a “type of chronic nonerosive gastritis characterized by infiltration of the lamina
propria by inflammatory cells, similar to superficial gastritis but involving the entire mucosa. The amount
of chief cells and parietal cells decreases, lymphoid nodules may be present, the total thickness of the
mucosa decreases, and intestinal metaplasia may develop.” Atrophic gastritis, DORLAND’S at 754.
28
Osteoarthritis is a “noninflammatory degenerative joint disease seen mainly in older persons,
characterized by degeneration of the articular cartilage, hypertrophy of bone at the margins, and changes in
the synovial membrane. It is accompanied by pain, usually after prolonged activity, and stiffness,
particularly in the morning or with inactivity.” Osteoarthritis, DORLAND’S at 1326.
29
A hemorrhoid is a “prolapse of an anal cushion, resulting in bleeding and painful swelling in the anal
canal.” Hemorrhoid, DORLAND’S at 832.

11
disorder was causing his symptoms. Id. Dr. Weber attributed petitioner’s anemia to
hypochlorhydria30 from autoimmune gastritis and/or pernicious anemia. Id.

On August 12, 2015, petitioner returned to Dr. Salser with ongoing knee “tissue disorder,”
or “connective tissue disease [is] connected to Hep B vaccine” and requested referral to a
rheumatologist who specialized in muscular disorders. Pet. Ex. 3 at 64. Dr. Salser documented
petitioner’s mood and behavior as “flat” and “restless.” Id. at 68.

On August 18, 2015, petitioner returned to Dr. Agnihotri. Pet. Ex. 3 at 59; Pet Ex. 1 at 60.
He complained of crackling joints and stiffness in his muscles and arms “focus[ed] on how this
could be Hep vaccine related.” Id. at 60. He worried his joint problems were secondary to muscle
weakness due to MS. Id. Dr. Agnihotri noted EMG results with no significant abnormalities and
normal physical exam. Id. at 62-63. Dr. Agnihotri wrote symptoms could be due to his vitamin
B12 deficiency and “reinforced that there’s no evidence of MS…” Id. Dr. Agnihotri agreed to
order a brain MRI at petitioner’s request, which she “expected to be normal.” Id. at 63. She
“remain[ed] concerned about some degree of somatization or somatiform (sic) disorder.” Id. She
discussed how anxiety and stress could contribute to his symptoms but petitioner “firmly denie[d]
that.” Id.

Petitioner had a brain MRI with and without contrast on August 26, 2015, which showed
“[s]mall nonspecific abnormal signal foci in the left frontal white matter” which “may represent
chronic microvascular disease and do not have the classic appearance expected for demyelinating
disease. No acute intracranial abnormality.” Pet. Ex. 12 at 15-16.

Petitioner had an abdominal MRI on August 27, 2015, which showed no evidence of
inflammatory bowel disease or small bowel mass. Pet. Ex. 12 at 17-18.

On August 28, 2015, petitioner returned to Dr. Smith with complaints of joint pain in his
left elbow with popping and cracking in both knees. Pet. Ex. 3 at 70. Petitioner reported being
unable to run, but upon further questioning by Dr. Smith, admitted that “he actually had not tried
to run because he is concerned that this may be painful or possibly cause injury.” Id. at 71. Dr.
Smith wrote petitioner “still expressed concern that his symptoms are the result of ‘hepatitis B
vaccine injury,’” stating “I feel the autoimmune reaction,” as well as “twitching of the muscles.”
Id. at 70. He “described articles that indicate long term chronic joint damage related to a hepatitis
B vaccination.” Id. at 71. He requested muscle biopsy as well as synovial biopsy to investigate his
symptoms. Id. Physical examination was normal with no evidence of an inflammatory arthritic
condition. Id. at 76. Dr. Smith agreed with Dr. Agnihotri that petitioner’s symptoms were likely
due to somatization. Id. at 77.

Dr. Smith wrote, “[petitioner] told me, ‘I expect aggressive diagnostics and appropriate
treatment.’” Pet. Ex. 3 at 71. He provided contact numbers for Merck and suggested that Dr. Smith
call them to discuss his condition. Id. He was concerned he was “deteriorating,” and requested

30
Hypochlorohydria is a “deficiency of hydrochloric acid in the gastric juice.” Hypochlorohydria,
MERRIAM-WEBSTER ONLINE DICTIONARY, https://www.merriam-webster.com/medical/hypochlorhydria
(last visited Mar. 27, 2020).

12
MRIs of all of his painful joints, which Dr. Smith refused to order but did order a separate list of
tests and “emphasize[d] that [the] labs tests (sic) are non-specific and would neither rule in or rule
out any disease.” Id. at 76. Dr. Smith wrote petitioner “expressed desire to see someone else in my
department who is an expert in hepatitis B vaccine injury.” Id. Additionally, petitioner “strongly
expressed a desire” that Dr. Smith immediately review the case with the clinic director, Dr.
Chatham. Id. When Dr. Smith advised that would take a few weeks “to allow for a more productive
assessment,” petitioner became “upset” and “insisted that he should get an immediate
appointment” with Dr. Chatham. Id. Dr. Smith notified Dr. Chatham of the situation and told
petitioner “there is no need for further follow up with me.” Id.

On September 8, 2015, petitioner returned to Dr. Salser with complaints of joint pain in
both knees and left elbow as a result of a hepatitis B vaccine he received in 2013. Pet. Ex. 3 at 53.
Dr. Salser described petitioner as “Anxious, Angry,” his behavior as “Belligerent, Compulsive,”
and flagged petitioner as having “Abnormal/Psychotic thoughts.” Id. at 57. Petitioner demanded
“Urgency at the highest level” and requested a “specialist who understands Hep B adverse effects.”
Id. Petitioner was very upset because “Nobody [was] helping [him] discover the diagnosis on this”
and “[he had] to continue to research this because nobody [was] helping [him].” Id. at 53. Dr.
Salser noted that a recent abdominal MRI showed no evidence of inflammatory bowel disease. Id.
at 54.

On October 1, 2015, petitioner returned to Dr. Weber complaining of recurrent rectal
bleeding. Pet. Ex. 3 at 48. Dr. Weber wrote petitioner has “significant rheumatologic complaints
with no defined diagnosis” though “he does seem to blame this on a hepatitis B vaccine.” Id. “The
symptoms are intermittent but he worries about them constantly—although more so his
rheumatologic complaints.” Id. An abdominal MRI was normal, though petitioner did have a
modest iron deficiency. Id. at 49. Dr. Weber’s diagnoses were chronic atrophic gastritis without
bleeding, unspecified iron deficiency anemia, unspecified vitamin D deficiency, and possible
somatization. Id. at 51.

At his insistence, Dr. Chatham head of rheumatology at Kirklin Clinic examined petitioner
on October 12, 2015. Pet. Ex. 3 at 42. Petitioner reported good health until the past year, when he
began to experience increasing difficulties with joint pain, muscle twitches, and crepitation in his
neck, elbows, shoulders, and knees with generalized myalgia and weakness that significantly
interfered with function. Id. Dr. Chatham wrote, “[petitioner] has had numerous serologic as well
as imaging evaluations done in the past year all of which have been unrevealing for any evidence
of acute phase response, autoantibody titer elevations, rheumatoid factor elevation or any evidence
of inflammatory changes referable to his knees.” Id. Additionally, all MRIs have been
unremarkable. Id. at 42-43. “It is possible his arthralgias were accentuated by adjuvants in the
administered HBV vaccine, but there is no objective evidence of chronic joint inflammation
presently. Current objective findings on exam and imaging are all easily explained by evolving
osteoarthritis” Id. at 46. Petitioner tested positive for HLA-B27, which is a gene found in 90% of
patients with ankylosing spondylitis. Id. at 47; see also Histocompatibility complex, STEDMAN’S
at 194270. Dr. Chatham prescribed sulfasalazine.31 Id.

31
Sulfasalazine is an anti-inflammatory drug used to treat ulcerative colitis, Crohn’s disease, and
rheumatoid arthritis. Sulfasalazine – Drug Summary, PDR.NET, https://www.pdr.net/drug-
summary/Azulfidine-sulfasalazine-1862#14 (last visited Mar. 27, 2020).

13
 On October 15, 2015, petitioner returned to Dr. Salser for follow-up of ongoing knee,
elbow, and shoulder pain. Pet. Ex. 3 at 37. He reported a “twitching” sensation in both upper arms
and expressed interest in seeing an integrative medicine physician. Id. Petitioner was scheduled
for a capsule endoscopy with his gastroenterologist later that day. Id. Dr. Salser agreed to refer
him to Dr. Allen. He was to follow-up in two months. Id. at 41.

On October 16, 2015, petitioner was admitted to UAB by Dr. Vander Noot for a suspected
gastrointestinal bleed and inability to pass the capsule from an endoscopy the prior day despite
multiple bowel movements.32 Pet. Ex. 1 at 399, 457, 465. The capsule endoscopy was done to
determine if a source other than pre-existing hemorrhoids was the cause of his bleeding. Id. at 470.
Petitioner reported abdominal pain and rectal bleeding for four hours and was admitted for two
days. Id. at 465, 579-82. There was blood observed in petitioner’s stool, but no apparent source
was located. Id. at 467. Petitioner was kept under observation. He was concerned that the capsule
had broken and irritated his bowels. Id. at 467, 470, 478. Radiology found no evidence of a bleed
within the intestines and a CT scan identified the capsule in an appropriate position. Id. at 467,
477, 480-81, 485, 486, 492-93; Pet. Ex. 12 at 20-24. The minimal amount of blood was explained
by a pre-existing hemorrhoid. Id. at 467. Petitioner was advised that the capsule would pass
uneventfully and to follow-up with his primary care physician and gastroenterologist. Id. at 418,
486.

On November 18, 2015, petitioner returned to Dr. Salser following his admission to UAB
for what he reported as a “gastrointestinal bleed.” Pet. Ex. 1 at 105; Pet. Ex. 3 at 31-36. Petitioner
was taking sulfasalazine for ten days and claimed it helped with twitching, stiffness, and his B12
deficiency. Id. at 105. Dr. Salser noted, “Patient feels this is connected to his HLA B27 and Hep
B vaccination.” Id. at 106.

On December 22, 2015, petitioner returned to Dr. Salser with complaints of neck and knee
pain. Pet. Ex. 3 at 25. He was worried about an adjuvant reaction to the hepatitis B vaccine and
requested his aluminum level be checked. Id. Bloodwork was ordered. Id. at 29-30.

On January 29, 2016, petitioner returned to Dr. Chatham for “[s]uspected (undifferentiated)
spondyloarthropathy.33” Pet. Ex. 3 at 19. Petitioner complained of ongoing myalgia but stated that
his overall joint pain had improved, though crepitation of the left elbow and both knees was still
present. Id. Laboratory results were “unremarkable.” Id. at 24.

On February 15, 2016, petitioner returned to Dr. Salser with ongoing pain in his elbow,
knee, neck, and upper shoulder as well as “muscle fatigue” which “[c]omes and goes”. Pet. Ex. 3
at 13-14. Dr. Salser wrote petitioner “did literature search – Vitamin D helps with symptoms of
Hepatitis B Vaccine.” Id. At the request of the petitioner, autoimmune tests were reordered. Id. at
17.

32
Records documenting the capsule endoscopy could not be located.
33
Spondyloarthropathy is a “[d]isease of the joints of the spine.” Spondyloarthropathy, DORLAND’S at
1725.

14
 On February 26, 2016, petitioner returned to Dr. Agnihotri with complaints of intermittent
muscle fatigue. Pet. Ex. 3 at 7-8. He reported pain in the left side of his body, from his shoulder to
his upper hip, the week prior. Id. at 8. He also reported having short term memory loss after
receiving a hepatitis B vaccination, which had since improved. Id. Petitioner worried he could have
macrophagic myofasciitis34 associated with aluminum adjuvants; Dr. Agnihotri wrote, “he again
focuses on how this could be Hep vaccine and the adjuvants in the vaccine.” Id. Petitioner advised
that he was taking cilantro and chlorella supplements to counteract aluminum toxicity. Id.
Petitioner further expressed concern for myopathy secondary to the hepatitis B vaccine and
presented related literature. Id. at 11. Dr. Agnihotri assured him there was no evidence of myopathy
on the EMG, and therefore no need for a muscle biopsy. Id. Petitioner was “reassured multiple
times and again today that there is no evidence of MS at this time,” as he was diagnosed with a
significant vitamin B12 deficiency which would explain most of his symptoms. Id. Dr. Agnihotri
wrote there was no objective neurological evidence that petitioner developed an autoimmune
reaction after the hepatitis B vaccination. Id. Dr. Agnihotri again expressed concern that petitioner
was suffering from “some degree of somatization or somatiform (sic) disorder,” and suggested
counselling or therapy, which petitioner refused. Id.

On March 18, 2016, petitioner returned to Dr. Salser with complaints of chronic fatigue
and multiple musculoskeletal complaints, including “tissue discomfort” on the left side of his body,
“which he relates to receiving ‘all 3 Hep B injections in my left arm.’” Pet. Ex. 3 at 1. Petitioner
was worried about hair loss he stated began after the hepatitis B vaccinations. Id. at 2. “Patient
states he needs my opinion on whether this is truly a Hepatitis B Vaccination injury.” Id. Dr. Salser
wrote petitioner “presented multiple articles about Hep B vaccination injury” and “continued to
insist on treatment plans, literature researches (sic) and treatment for Hep B vaccination injury.”
Id. at 6. Dr. Salser advised petitioner that his anxiety was exacerbating his complaints and offered
a referral to a psychiatrist, but petitioner “adamantly refused any psych meds or referral.” Id.

On April 12, 2016, petitioner returned to Dr. Chatham, complaining of possible gluten
sensitivity, left-side chest wall pain, and ocular discomfort. Pet. Ex. 13 at 68. His joint pain had
improved, and he no longer had swelling, though crepitation was noted in the left elbow. Id. He
was diagnosed with osteoarthritis of the neck, knee, and left elbow along with myalgias. Id. at 72.
Possible uveitis35 was noted. Id.

On May 31, 2016, petitioner visited Dr. Gewin, a specialist in family and internal medicine,
reporting multiple rheumatologic complaints, diagnoses of pernicious anemia, atrophic gastritis,
positive HLA-B27, vitamin B12 deficiency, and “undifferentiated connective tissue disease by his
rheumatologist Dr. Chatham.” Pet. Ex. 15 at 5. Petitioner questioned Dr. Gewin whether these
problems were caused by the hepatitis B vaccine. Id. Petitioner described worsening hair loss and
itching as well. Id. He wanted testing for celiac disease and Hashimoto’s thyroiditis. Id. Bloodwork
revealed normal TSH, normal antibodies, and normal tissue transglutaminase. Id. at 4.

34
Myofasciitis is an “inflammation of a muscle and its fascia, particularly of the fascial insertion of muscle
to bone.” Myofasciitis, DORLAND’S at 1205.
35
Uveitis is “an inflammation of part or all of the uvea, commonly involving the other tunics of the eye
(sclera, cornea, and retina).” Uveitis, DORLAND’S at 1983.

15
 On July 26, 2016, petitioner returned to Dr. Chatham for ongoing myalgias and occasional
fasciculations.36 Pet. Ex. 13 at 76. He had mild pruritus but no rash, and his overall joint pains had
further improved. Id. An x-ray of his elbow was performed and did not show fracture, dislocation,
or swelling. Id. at 83. Early osteoarthritis signs were observed from the knee exam and probable
osteoarthritis of the left elbow was indicated. Id. at 79. Petitioner was “[t]olerating sulfasalazine
well.” Id. at 76.

On August 19, 2016, petitioner returned to Dr. Gewin complaining of worsening arthralgias
in his left elbow and knee. Pet. Ex. 15 at 5. He again related the arthralgias to his hepatitis B
vaccines because they were given when he had extreme pruritis, crepitus, and pain in his joints.
Id. Dr. Gewin noted a possible immune response to the vaccines, including arthralgias and allergic
dermatitis that had since resolved. Id. Dr. Gewin ordered a rheumatoid profile with serologic
markers, including the sedimentation rate37 and CRP.38 Id. The bloodwork revealed negative
ANA,39 abnormally low ferritin,40 normal rheumatoid factor, and normal TSH. Id. at 6.

On August 26, 2016, petitioner returned to Dr. Gewin reporting when he tried to
discontinue the vitamin D supplements, he noticed more pain and spasticity in his joints. Pet. Ex.
15 at 4. Dr. Gewin instructed petitioner to continue the vitamin D supplement and planned to test
petitioner’s vitamin D 25-hydroxy level at the next appointment. Id. Petitioner apparently did not
return to Dr. Gewin, as there are no further records.

On August 29, 2016, petitioner presented to Dr. Nozaki for a second opinion of whether
the hepatitis B vaccine caused his myalgias. Pet. Ex. 13 at 84-85. Dr. Nozaki wrote that petitioner
contacted a physician in France who thinks hep B vaccination can cause MS and myopathy.” Id.
at 84. He was concerned he could have macrophagic myofasciitis from the aluminum adjuvants in
the vaccine. Id. at 85. Petitioner also complained of muscle fatigue that was “on and off.” Id. On
examination he was found to have normal strength, sensory response, and DTRs.41 Id. at 87. There

36
Fasciculations are involuntary contractions of groups of muscle fibers. Fasciculation, STEDMAN’S at
321740.
37
Sedimentation rate is a non-specific test used to detect illnesses associated with acute and chronic
infection, inflammation, and tissue necrosis or infarction. See Mosby’s Manual of Diagnostic and
Laboratory Tests 199 (Pagana eds., 6th ed. 2018) [hereinafter Mosby’s].
38
C-reactive protein (“CRP”) is a protein used to indicate an inflammatory illness. It is elevated in patients
with a bacterial infectious disease, tissue necrosis, or an inflammatory disorder. A positive test result
indicates the presence, but not the cause, of the disease. See Mosby’s at 165-66.
39
“ANA” stands for “anti-nuclear antibody.” It is an antibody showing an affinity for nuclear antigens
including DNA and found in the serum of a high proportion of patients with systemic lupus erythematosus,
rheumatoid arthritis, and certain collagen diseases. Anti-nuclear antibody (ANA), STEDMAN’S at 47140.
40
Ferritin is an iron-protein complex which regulates iron storage and transport. Ferritin, STEDMAN’S at
324990.
41
“DTR” stands for deep tendon reflex. DTR, STEDMAN’S at 267760. Deep tendon reflexes are involuntary
contractions of skeletal muscle that occur as a result of stimulation of stretch receptors in the muscles. Deep
tendon reflex, id. at 767400; myotatic contraction, id. at 201140.

16
was no evidence of myalgias, rashes, or joint swelling. Id. Dr. Nozaki concluded petitioner may
have had a systemic autoimmune reaction to the vaccine, but ongoing myopathy was unlikely due
to his normal strength and lack of myalgia. Id. at 88.

On October 14, 2016, petitioner returned to Dr. Chatham with noted “suspected
(undifferentiated) spondyloarthropathy.” Pet. Ex. 19 at 137. Petitioner reported Dr. Weber advised
him he has atrophic gastritis with anti-parietal cell abnormality. Id. Bloodwork was ordered and
was unremarkable. Id. at 141-42.

On December 14, 2016, petitioner presented to Dr. McLain, a specialist in internal
medicine reporting that he had UCTD, positive HLA-B27, joint pain, and a “Hepatitis B vaccine
reaction.” Pet. Ex. 28 at 1. Dr. McLain wrote he has “a number of symptoms that he links to
hepatitis B vaccination.” Id. at 5. Petitioner was taken off sulfasalazine and placed on Plaquenil.42
Id.

On January 31, 2017, petitioner returned to Dr. Chatham, for “suspected (undifferentiated)
spondyloarthropathy.” Pet. Ex. 19 at 114. He complained of ongoing knee pain, elbow arthralgia,
crepitation referable to left elbow and both knees, and no rash or joint swelling but ongoing
stiffness in his elbow. Id. He was tolerating sulfasalazine and had no diarrhea, weight loss, or new
ocular complaints. Id. He was feeling better overall. Id. He was minimizing gluten in his diet and
adhering to a regular exercise program. Id. Dr. Chatham’s impression was cervical, knee, and left
elbow osteoarthritis, and myalgia. Id. at 118.

On February 3, 2017, petitioner underwent an MRI of his left elbow to evaluate for
synovitis43/enthesitis.44 Pet. Ex. 19 at 110. The MRI was “[e]ssentially unremarkable” and “[n]o
abnormality [was] identified to account for patient’s elbow pain.” Id.

On April 11, 2017, petitioner presented to Dr. Massey at Alabama Allergy complaining of
itchy legs, skin rash, knee and elbow discomfort, intermittent eye discomfort, hair loss, and
atrophic gastritis connected to the hepatitis B vaccine. Pet. Ex. 29 at 2. Petitioner was not
hypersensitive to any of the following allergens: corn, egg white, milk, peanut, soybean, or wheat.
Id. at 1. Zyrtec was recommended to aid with itching. Id. at 2.

42
Plaquenil is the brand name for hydroxychloroquine sulfate, an anti-rheumatic drug used to treat
rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and malaria. Hydroxychloroquine
sulfate – Drug Summary, PDR.NET, https://www.pdr.net/drug-summary/Plaquenil-hydroxychloroquine-
sulfate-1911 (last visited Mar. 27, 2020).
43
Synovitis is “inflammation of a synovial membrane; it is usually painful, particularly on motion, and is
characterized by a fluctuating swelling due to effusion within a synovial sac.” Synovitis, DORLAND’S at
1826.
44
Enthesitis is “inflammation of the muscular or tendinous attachment to bone.” Enthesitis, DORLAND’S at
620.

17
 On April 13, 2017, petitioner presented to Callahan Eye Clinic for an eye evaluation on
referral by Dr. Chatham. Pet. Ex. 18 at 1. He complained of halos and pain around his eyes. No
ocular etiology was found. Id. at 5. The pain was attributed to dry eyes or sinus problems. Id.

On April 25, 2017, petitioner returned to Dr. Chatham with ongoing knee and left elbow
arthralgia and crepitation. Pet. Ex. 19 at 87. He reported overall improvement in joint pain but had
twitching and stiffness. Id. There was no sign of uveitis. Petitioner was concerned that he had an
allergy to proteins due to his pruritis and occasional rashes. Id. Petitioner was “[s]till submitting
claim to vaccine injury board (sic) alleging his medical problems arose from previous HBV
vaccine.” Id. at 87.

On May 7, 2017, Dr. Chatham sent an email to petitioner which stated: “Subject: RE:
Chatham, Walter Winn – Rheumatology: Diagnosis – Right elbow crepitation in 2015. As
previously stasted (sic) your diagnosis(sic) are: seronegative spondyloarthropathy45 osteoarthritis
of the cervical spine, knees.” Pet. Ex. 14.46

On August 7, 2017, petitioner presented to Dr. Wilcox, a gastroenterologist, with
“numerous complaints” which petitioner “link[ed]…to a series of hepatitis B injections in 2015.”
Pet. Ex. 19 at 57. He reported his knees and elbows “pop” with movement, but an MRI of his left
elbow was unremarkable. Id. at 60, 62. Petitioner was “concerned about “leaky gut” caused by the
vaccination.” Dr. Wilcox was unable to “link any of his complaints to some specific bowel
disease.” Id. at 62. Petitioner requested an investigation into inflammatory bowel disease. Dr.
Wilcox ordered tissue transglutaminase and antiparietal cell antibody panels. Id. Tissue
transglutaminase was negative. Id. at 63-64. Anti-gastric parietal cell antibodies were positive; Dr.
Wilcox concluded the result “may reflect the presence of atrophic gastritis.” Id. at 62-63.

On January 5, 2018, petitioner returned to Dr. Wilcox for flexible sigmoidoscopy of the
colon. Pet. Ex. 19 at 7-10. Minimal amounts of chronic inflammation were observed. Id. at 8. Skin
tags and a healed fistula were also found. Id. at 9. There was minor irritation at the dentate line,
but no bleeding present. Id. Petitioner was advised to use fiber supplements. Id. at 10.

On March 26, 2018, petitioner returned to Dr. Chatham. Pet. Ex. 31 at 11. Petitioner had
stopped using sulfasalazine and only used NSAIDs and glucosamine, as needed. Id. He denied any
ocular complaints and had no new gastrointestinal complications. Id. Dr. Chatham wrote petitioner
has “early [osteoarthritic] changes referable to knee by exam, MR; cervical disc disease by cervical
radiogrpahs (sic), MR; probably component of post-traumatic [osteoarthritis] of the left elbow.”
Id. at 13.

45
Ankylosing spondylitis, also referred to as seronegative spondyloarthropathy, is “a general term
comprising a number of degenerative joint diseases having common clinical, immunologic, pathologic, and
radiographic features, including synovitis of the peripheral joints, enthesopathy, bony ankylosis of the large
peripheral joints, lack of rheumatoid factor, and, in many cases, a positive status for the human leukocyte
antigen HLA-B27.” Seronegative spondyloarthropathy, DORLAND’S at 1725.
46
The request to Dr. Chatham that resulted in this email was not filed.

18
 On April 10, 2018, an MRI of petitioner’s hips revealed a right acetabular labral tear but
no evidence of synovitis. Pet. Ex. 31 at 18. An MRI of the thoracic spine on April 11, 2018 revealed
persistent disc protrusion at the T1-2 and decreased mass effect on the thoracic cord, but no focal
cord signal abnormalities. Id. at 20.

On January 30, 2019, petitioner presented to Dr. Lolley, an ophthalmologist at Callahan
Eye Hospital Clinic, for pain behind the left eye and light sensitivity. Pet. Ex. 32 at 1. Petitioner
“believe[d] these symptoms are related to dx (sic) of Ankylosing spondylitis that he developed
after receiving a Hep B vaccine.” Id. Dr. Lolley diagnosed petitioner with keratoconjunctivitis
sicca47 and myopia48 with presbyopia49 in both eyes. Id. at 4. Petitioner expressed concern that his
vision would change but was informed his condition was common in patients who had Lasik
surgery performed in 1998. Id. at 5. Petitioner noted frequent tears, despite the diagnosis of
keratoconjunctivitis sicca. Id. Allergies to “Hepatitis B virus vaccine” and oxycodone were
reported. Id. at 1-2.

On February 26, 2019, petitioner presented to Dr. Read, an ophthalmologist at Callahan
Eye Hospital Clinic for evaluation. He reported receipt of a hepatitis B vaccine after which “he
suffered severe damage from this…he had 2 in 2013…last shot in 2017.” Pet. Ex. 33 at 1. He
reported light sensitivity, headaches, blurred vision and halos at night. Id. He had vitamin B12
deficiency and “some other auto immune disorders that he feels may be affecting OU. He had a
follow up with Dr. Lolley and received a new prescription for glasses. Id. at 1-2. Dr. Read’s
assessment was ankylosing spondylitis, unspecified site of spine; HLA-B27 positive; history of
assisted in situ keratomileusis; blepharitis50 of both eyes unspecified eyelid, unspecified type;
keratoconjunctivitis sicca of both eyes. Id. at 4. The plan was to return as needed. Id.

No further medical records were filed.

F. Letters from Dr. W Winn Chatham, Professor of Medicine

On March 8, 2018, Dr. Chatham submitted a letter with the salutation “To whom it may
concern.”51 Pet. Ex. 17 at 1. Dr. Chatham wrote that he first examined petitioner on October 12,
2015, when petitioner presented with a history of symmetric joint pain and stiffness referable to
his elbows, knees and cervical. Id. Petitioner reported onset of symptoms subsequent to “initiation

47
Keratoconjunctivitis sicca is “a condition marked by hyperemia of the conjunctiva, lacrimal deficiency,
thickening of the corneal epithelium, itching and burning of the eye, and often reduced visual acuity.”
Keratoconjunctivitis sicca, DORLAND’S at 968.
48
Myopia is “an error of refraction in which rays of light entering the eye parallel to the optic axis are
brought to focus in front of the retina, as a result of the eyeball being too long from front to back, or of an
increased strength in refractive power of the media of the eye.” Myopia, DORLAND’S at 1207.
49
Presbyopia is “impairment of vision due to advancing years or to old age.” Presbyopia, DORLAND’S at
1488.
50
Blepharitis is “inflammation of the eyelids.” Blepharitis, DORLAND’S at 221.
51
To whom or why this letter was written is unclear.

19
of an immunization series with Hepatitis B vaccine.” Id. Evaluation was negative for serologic
evidence for developing rheumatoid arthritis or a lupus-related autoimmune disease. Id. He was
confirmed to be a positive HLA-B27 carrier. Id. He also had iron deficiency and a history of
previous rectal fistula. Id. Developing spondyloarthropathy related to inflammatory bowel disease
was considered but not confirmed after an extensive work-up. Id. There were no skin lesions to
implicate developing psoriatic arthritis or gastrointestinal or genitourinary infection to implicate
developing reactive arthritis. Id. Due to the above and recent symptoms of inflammatory lower
back pain, he was being treated with sulfasalazine and NSAIDs for developing
spondyloarthropathy, most consistent with ankylosing spondylitis. Id. Dr. Chatham concluded
that his symptoms had only been present for three years, so he had not yet developed any
radiographic footprints characteristic of this disorder. Id.

On April 27, 2018, Dr. Chatham generated a second letter, again directed “To whom it may
concern.” Pet. Ex. 30 at 1. He wrote:

This patient continues to be followed in the UAB Rheumatology Clinic for
developing ankylosing spondylitis that presented with seronegative symmetric
arthritis, axial pain, stiffness in the context of HLA-B27 positive haplotype. He
presented to our clinic with this complex of symptoms in 2015 following initiation
of immunization with hepatitis B vaccine in 2014. As such, it is more likely than
not that the vaccine triggered the onset of his disease.

Id.

G. Affidavit of P.S.

The only Affidavit submitted by the petitioner can be found at the end of the Petition, in
which the petitioner affirms that the statements contained in the Petition are true except where the
statements are made “upon information and belief,” in which case they are true based on the
information “now available to me.” Pet. at 13, ECF No. 1.

II. Legal Standard

The Vaccine Act provides petitioners with two avenues to receive compensation for their
injuries resulting from vaccines or their administration. First, a petitioner may demonstrate that he
or she suffered a “Table” injury—i.e., an injury listed on the Vaccine Injury Table that occurred
within the provided time period. § 11(c)(1)(C)(i). “In such a case, causation is presumed.”
Capizzano v. Sec’y of Health & Human Servs., 440 F.3d 1317, 1320 (Fed. Cir. 2006); see §
13(a)(1)(B). Alternatively, where the alleged injury is not listed on the Vaccine Injury Table, a
petitioner may bring an “off-Table” claim. § 11(c)(1)(C)(ii). An “off-Table” claim requires that
the petitioner “prove by a preponderance of the evidence that the vaccine at issue caused the
injury.” Capizzano, 440 F.3d at 1320; see § 11(c)(1)(C)(ii)(II). Initially, a petitioner must provide
evidence that he or she suffered, or continues to suffer, from a definitive injury. Broekelschen v.
Sec’y of Health & Human Servs., 618 F.3d 1339, 1346 (Fed. Cir. 2010). A petitioner need not
show that the vaccination was the sole cause, or even the predominant cause, of the alleged injury;
showing that the vaccination was a “substantial factor” and a “but for” cause of the injury is

20
sufficient for recovery. See Pafford v. Sec’y of Health & Human Servs., 451 F.3d 1352, 1355 (Fed.
Cir. 2006); Shyface v. Sec’y of Health & Human Servs., 165 F.3d 1344, 1352 (Fed. Cir. 1999).52

To prove causation, petitioners must satisfy the three-pronged test established in Althen v.
Sec’y of Health & Human Servs., 418 F.3d 1274 (Fed. Cir. 2005). Althen requires that petitioners
show by preponderant evidence that a vaccination petitioner received caused his or her injury “by
providing: (1) a medical theory causally connecting the vaccination and the injury; (2) a logical
sequence of cause and effect showing that the vaccination was the reason for the injury; and (3) a
showing of a proximate temporal relationship between vaccination and injury.” Id. at 1278.
Together, these prongs must show “that the vaccine was ‘not only a but-for cause of the injury but
also a substantial factor in bringing about the injury.’” Stone v. Sec’y of Health & Human Servs.,
676 F.3d 1373, 1379 (Fed. Cir. 2012) (quoting Shyface, 165 F.3d at 1352-53). Causation is
determined on a case-by-case basis, with “no hard and fast per se scientific or medical rules.”
Knudsen v. Sec’y of Health & Human Servs., 35 F.3d 543, 548 (Fed. Cir. 1994). Petitioners are not
required to identify “specific biological mechanisms” to establish causation, nor are they required
to present “epidemiologic studies, rechallenge, the presence of pathological markers or genetic
disposition, or general acceptance in the scientific or medical communities.” Capizzano, 440 F.3d
at 1325 (quoting Althen, 418 F.3d at 1280). “[C]lose calls regarding causation are resolved in favor
of injured claimants.” Althen, 418 F.3d at 1280.

Each of the Althen prongs requires a different showing. Under the first Althen prong,
petitioner must provide a “reputable medical theory” demonstrating that the vaccine received can
cause the type of injury alleged. Pafford, 451 F.3d at 1355-56 (citation omitted). To satisfy this
prong, a theory must be sound and reliable. A petitioner’s “plausible” or “possible” causal theory
does not satisfy the standard of proof in Vaccine Act cases. Boatmon v. Sec’y of Health & Human
Servs., 941 F.3d 1351, 1360 (Fed. Cir. 2019). This theory need only be “legally probable, not
medically or scientifically certain.” Id. at 1380 (emphasis omitted) (quoting Knudsen, 35 F.3d at
548). Nevertheless, “petitioners [must] proffer trustworthy testimony from experts who can find
support for their theories in medical literature.” LaLonde v. Secretary of Health & Human Servs.,
746 F.3d 1334, 1341 (Fed. Cir. 2014).

The second Althen prong requires proof of a “logical sequence of cause and effect.”
Capizzano, 440 F.3d at 1326 (quoting Althen, 418 F.3d at 1278). Even if the vaccination can cause
the injury, petitioner must show “that it did so in [this] particular case.” Hodges v. Sec’y of Health
& Human Servs., 9 F.3d 958, 962 n.4 (Fed. Cir. 1993) (citation omitted). “A reputable medical or
scientific explanation must support this logical sequence of cause and effect,” id. at 961 (citation
omitted), and “treating physicians are likely to be in the best position to determine whether a
logical sequence of cause and effect show[s] that the vaccination was the reason for the injury,”
Paluck v. Sec’y of Health & Human Servs., 786 F.3d 1373, 1385 (Fed. Cir. 2015) (quoting Andreu,
569 F.3d at 1375).

52
The Vaccine Act also requires petitioners to show by preponderant evidence the vaccine suffered from
the “residual effects or complications” of the alleged vaccine-related injury for more than six months, died
from the alleged vaccine-related injury, or required inpatient hospitalization and surgical intervention as a
result of the alleged vaccine-related injury. § 11(c)(1)(D). It is undisputed that this requirement is satisfied
in this case.

21
 The third Althen prong requires that petitioner establish a “proximate temporal
relationship” between the vaccination and the alleged injury. Althen, 418 F.3d at 1281. This
“requires preponderant proof that the onset of symptoms occurred within a timeframe for which,
given the medical understanding of the disorder’s etiology, it is medically acceptable to infer
causation-in-fact.” De Bazan v. Sec’y of Health & Human Servs., 539 F.3d 1347, 1352 (Fed. Cir.
2008). Typically, “a petitioner’s failure to satisfy the proximate temporal relationship prong is due
to the fact that onset was too late after the administration of a vaccine for the vaccine to be the
cause.” Id. However, “cases in which onset is too soon” also fail this prong; “in either case, the
temporal relationship is not such that it is medically acceptable to conclude that the vaccination
and the injury are causally linked.” Id.; see also Locane v. Sec’y of Health & Human Servs., 685
F.3d 1375, 1381 (Fed. Cir. 2012) (“[If] the illness was present before the vaccine was administered,
logically, the vaccine could not have caused the illness.”).

A petitioner may also be eligible for compensation if he or she had a preexisting condition
which was significantly aggravated by a vaccine. See § 11(c)(1)(C). For a significant aggravation
claim for an off-Table injury, the petitioner’s burden is raised, requiring petitioner to show, by
preponderant evidence, proof of

(1) the person’s condition prior to administration of the vaccine, (2) the person’s
current condition (or the condition following the vaccination if that is also
pertinent), (3) whether the person’s current condition constitutes a “significant
aggravation” of the person’s condition prior to vaccination, (4) a medical theory
causally connecting such a significantly worsened condition to the vaccination, (5)
a logical sequence of cause and effect showing that the vaccination was the reason
for the significant aggravation, and (6) a showing of a proximate temporal
relationship between the vaccination and the significant aggravation.

Loving ex rel. Loving v. Sec’y of Health & Human Servs., 86 Fed. Cl. 135, 144 (2009). The fourth,
fifth, and sixth factors are derived from Althen prongs one, two, and three, respectively. Id. The
Federal Circuit has agreed with this approach. See W.C. v. Sec’y of Health & Human Servs., 704
F.3d 1352, 1357 (Fed. Cir. 2013) (“We hold that the Loving case provides the correct framework
for evaluating off-table significant aggravation claims.”) Due to the requirement to prove
causation, one special master has recommended evaluating “the last three Loving factors first.”
Hennessey v. Sec'y of Health & Human Servs., No. 01–190V, 2009 WL 1709053, at *42 (Fed. Cl.
Spec. Mstr. May 29, 2009), motion for review denied, 41 Fed. Cl. 126 (2010).

However, the third Loving factor, determining whether the person suffered a “significant
aggravation” of his or her condition, leads to the question of what constitutes a significant
aggravation. Based on the legislative history and the language of the statute, it appears that
Congress intended for a “significant aggravation” of a condition to present rather dramatically. See
H.R. Rep. 908, 99th Cong.2d Sess. 1, reprinted in 1986 USCCAN 6287, 6356 (“This [significant
aggravation] provision does not include compensation for conditions which might legitimately be
described as preexisting (e.g., a child with monthly seizures who, after vaccination, has seizures
every three and a half weeks), but is meant to encompass serious deterioration (e.g., a child with
monthly seizures who, after vaccination, has seizures on a daily basis” (emphasis added)); see also
42 U.S.C. § 300aa-33(4) (“The term “significant aggravation” means any change for the worse in

22
a preexisting condition which results in markedly greater disability, pain, or illness accompanied
by substantial deterioration of health” (emphases added)).

Once a petitioner has established that his or her condition worsened post-vaccination, the
special master must determine “whether the change for the worse in [petitioner’s] clinical
presentation was aggravation or a natural progression” of the preexisting condition. Hennessey,
2009 WL 1709053 at *42. In doing so, special masters have relied on evidence supporting the
“typical” clinical course of the petitioner’s condition. See, e.g., Locane, 685 F. 3d at 1381-82
(Special master’s determination that petitioner’s Crohn’s disease was not significantly aggravated
by her hepatitis B vaccinations where her disease flare-ups after her first and third vaccinations
were typical of frequent flares in adolescents’ expected course of Crohn’s disease was reasonable);
Faoro v. Sec'y of Health & Human Servs., No. 10-704V, 2016 WL 675491, at *27 (Fed. Cl. Spec.
Mstr. Jan. 29, 2016), mot. for review denied, 128 Fed. Cl. 61 (Fed. Cl. Apr. 11, 2016) (finding that
“the vaccinations would not have changed her clinical course and thus, the vaccinations did not
significantly aggravate her preexisting condition”).

Finally, although this decision discusses much but not all of the evidence filed in detail,
the undersigned reviewed and considered all of the evidence filed in this matter, including but not
limited to the medical records and literature that was filed. See Moriarty ex rel. Moriarty v. Sec’y
of Health & Human Servs., 844 F.3d 1322, 1328 (Fed. Cir. 2016) (“We generally presume that a
special master considered the relevant record evidence even though [s]he does not explicitly
reference such evidence in h[er] decision.”); Simanski v. Sec’y of Health & Human Servs., 115
Fed. Cl. 407, 436 (2014) (“[A] Special Master is ‘not required to discuss every piece of evidence
or testimony in her decision.’” (citation omitted)), aff’d, 601 F. App’x 982 (Fed. Cir. 2015).

III. Discussion

A. Defined and Recognized Injury

The first step in any case is to “determine what injury, if any, was supported by the evidence
presented in the record.” Lombardi v. Sec’y of Health & Human Servs., 656 F.3d 1343, 1353 (Fed.
Cir. 2011). It is the petitioner’s burden to demonstrate that he actually suffers from the injuries he
has alleged. Hibbard v. Sec’y of Health & Human Servs., 698 F.3d 1358, 1364-65 (Fed. Cir. 2012).
“In the absence of a showing of the very existence of any specific injury[,]…the question of
causation is not reached.” Lombardi, 656 F.3d at 1353; Broekelschen, 618 F.3d at 1346 (explaining
that a vaccine-related injury “has to be more than just a symptom or manifestation of an unknown
injury.”); Stillwell v. Sec’y of Health & Human Servs., 118 Fed. Cl. 47, 56 (2014) (“[I]f the special
master finds, as a preliminary matter, that petitioner has failed to substantiate the alleged injury,
the special master need not apply the Althen test for causality.”). Thus, petitioner has the burden
of demonstrating what medically-recognized injury he suffers. Broekelschen, 618 F.3d at 1348;
see also Lasnetski v. Sec’y of Health & Human Servs., 128 Fed. Cl. 242 (2016), aff’d, 696 Fed.
Appx. 497 (Fed. Cir. 2017).

To determine whether a petitioner has adequately proven a demonstrable injury, a special
master must analyze the complete medical records filed into the record by petitioner. 42 U.S.C. §
300aa-11(c)(2). Medical records created contemporaneously with the events they describe are

23
presumed to be accurate and complete providing all relevant information on a petitioner’s health
problems. Cucuras v. Sec’y of Health & Human Servs., 993 F.3d 1525, 1528 (Fed. Cir. 1993).
Subsequent statements made by third parties that contradict contemporaneous medical records are
less persuasive to special masters than the medical records. Campbell ex rel. Campbell v. Sec’y of
Health & Human Servs., 69 Fed. Cl. 775, 779 (2006).

In his petition, petitioner alleged that he suffered from “undifferentiated connective tissue
disease (“UCTD”), autoimmune or atrophic gastritis, and other injuries” as a result of the hepatitis
B vaccinations. See Petition at 1.

In his Motion for Ruling on the Record, petitioner claims the vaccinations “caused him to
develop auto-immune gastritis, pernicious anemia (an auto-immune disease), ankylosing
spondylitis (an auto-immune disease), and ongoing injuries and damages…” Motion at 1. He relied
on the literature he filed to “show that his medical course and current illness are consistent with a
diagnosis of post-vaccination ankylosing spondylitis;” that the “[m]edical literature discusses the
pathogenesis of ankylosing spondylitis as including intestinal disorders, and therefore provides a
link between [petitioner’s] diagnosed illnesses – pernicious anemia associated with elevated anti-
gastric parietal cell anti-bodies/B12 deficiency, and ankylosing spondylitis;” and provides “the
association of rheumatic diseases with the hepatitis b (sic) vaccine, and therefore provides a link
between [petitioner’s] diagnosed illnesses – ankylosing spondylitis – with the vaccine…” Id. at 4,
7, 11.

In response to the petitioner’s Motion for Ruling on the record, respondent pointed to the
medical records stating petitioner’s treating physicians “did not settle on a consensus diagnosis for
his condition” and therefore, “petitioner arguably has not proven any particular diagnosis in
accordance with the preponderance standard.” Response at 5.

It is unclear when, from whom, or if petitioner was ever suspected of having UCTD. UCTD
appears in petitioner’s records for the first time on October 15, 2015 when he reported it to Dr.
Salser as a condition from which he suffered. Pet. Ex. 1 at 101-04. Dr. Salser included UCTD in
petitioner’s list of ongoing problems, but not in his list of diagnoses. Id. at 102, 104. Petitioner
later reported to Dr. Gewin on May 31, 2016, Dr. Nozaki on August 26, 2016, and Dr. McLain on
December 14, 2016, that was he was diagnosed with UCTD by Dr. Chatham. See Pet. Ex. 13 at
84; Pet. Ex. 15 at 5; Pet. Ex. 28 at 1. Though UCTD is included in petitioner’s list of ongoing
problems at visits with Dr. Chatham on January 29, 2016; October 14, 2016; and January 31, 2017;
none of his office visits mention UCTD, and Dr. Chatham never included UCTD among
petitioner’s diagnoses. See Pet. Ex. 3 at 19-24, 42-47; Pet. Ex. 13 at 68-72, 76-83; Pet. Ex. 19 at
115-18, 137-42; Pet. Ex. 31 at 11-13. Moreover, Dr. Chatham specifically diagnosed petitioner
with osteoarthritis and spondyloarthropathy. See Pet. Ex. 14 at 1. Dr. Chatham’s records repeatedly
provided the diagnoses of osteoarthritis and spondyloarthropathy, up through the last office visit
filed on March 16, 2018. Pet. Ex. 31 at 11, 13.

Petitioner further claims he suffers from ankylosing spondylitis. Ankylosing spondylitis is
defined in the literature as part of a larger group of diseases generally termed

24
“spondyloarthropathies,” Pet. Ex. 20 at 1;53 Pet. Ex. 25 at 1;54 Pet. Ex. 23 at 1,55 characterized by
inflammatory back pain, restricted spinal mobility, peripheral arthritis, enthesitis, and uveitis. Pet.
Ex. 25 at 1; Pet. Ex. 22 at 1.56 The difficulty in diagnosing patients with ankylosing spondylitis is
exemplified by the numerous changes that have been made to diagnostic criteria since the initial
criteria were developed in 1961. See Pet. Ex. 24 at 257 (Discussing the evolution of criteria for
ankylosing spondylitis and noting that revised criteria were issued in 1966, 1977, and 1984).
Despite the importance of early diagnosis, many patients have symptoms for years before receiving
a diagnosis of ankylosing spondylitis. See Pet. Ex. 20 at 2 (Study finding an average diagnosis
delay was six years); Pet. Ex. 21 at 258 (Noting that “eight to 11 years may pass between the first
symptoms of [ankylosing spondylitis] and its definitive diagnosis”); Pet. Ex. 22 at 2 (Study finding
an average diagnosis delay was six years); Pet. Ex. 23 at 1 (Noting that the diagnosis of ankylosing
spondylitis “is often delayed by 5-10 years”); Pet. Ex. 25 at 1 (Noting that “an average interval of
8-11 years has been reported” between “the onset of symptoms and the time of diagnosis”). This
delay is likely due to the diagnostic criterium requiring radiographic evidence of changes in the
sacroiliac joint. Pet. Ex. 20 at 1-2; Pet. Ex. 22 at 1; Pet. Ex. 23 at 1; Pet. Ex. 25 at 1.

Petitioner also submitted several articles on the relationship between a positive HLA-B27,
as “a major risk factor for ankylosing spondylitis.” Pet. Ex. 37 at 6;59 see also Pet. Ex. 40 at 260
associated with spondyloarthropathy, including…ankylosing spondylitis”); Pet. Ex. 44 at 361
(Stating that ankylosing spondylitis is “strongly associated” with HLA-B27).

53
Umit Dincer et al., Diagnosis Delay in Patients With Ankylosing Spondylitis: Possible Reasons and
Proposals For New Diagnostic Criteria, 27 CLIN. RHEUMATOL. 457-62 (2008), filed as “Pet. Ex. 20.”
54
Finbar O’Shea et al., The Challenge of Early Diagnosis in Ankylosing Spondylitis, 34 J. RHEUMATOL. 5-
7 (2007), filed as “Pet. Ex. 25.”
55
Salih Ozgocmen & Muhammad Asim Khan, Current Concept of Spondyloarthritis: Special Emphasis
on Early Referral and Diagnosis, 14 CURR. RHEUMATOL. REP. 409-14 (2012), filed as “Pet. Ex. 23.”
56
Mehrzad Hajialilo et al., Ankylosing Spondylitis in Iran; Late Diagnosis and Its Causes, 16 IRAN RED
CRESCENT MED. J. e11798 (2014), filed as “Pet. Ex. 22.”
57
Martin Rudwaleit et al., The Challenge of Diagnosis and Classification in Early Ankylosing Spondylitis:
Do We Need New Criteria?, 52 ARTHRITIS RHEUMATOL. 1000-08 (2005), filed as “Pet. Ex. 24.”
58
J. Martindale & L. Goodacre, The Journey to Diagnosis in AS/Axial SpA: The Impact of Delay, 12
MUSCULOSKELET. CARE 221-31 (2014), filed as “Pet. Ex. 21.”
59
Mary-Ellen Costello et al., Intestinal Dysbiosis in Ankylosing Spondylitis, 67 ARTHRITIS RHEUMATOL.
686-91 (2015), filed as “Pet. Ex. 36.”
60
James T. Rosenbaum et al., Does the Microbiome Cause B27-related Acute Anterior Uveitis?, 24 OCUL.
IMMUNOL. INFLAMM. 440-44 (2016), filed as “Pet. Ex. 40.”
61
James T. Rosenbaum & Mark Asquith, The Microbiome and HLA-B27-Associated Acute Anterior
Uveitis, 14 NAT. REV. RHEUMATOL. 704-13 (2018), filed as “Pet. Ex. 44.”

25
 Petitioner’s medical history prior to his hepatitis B vaccinations includes hair loss, itching,
cutis xerosis, urticaria, seborrheic dermatitis, folliculitis, upper abdominal pain, diarrhea, history
of rectal bleeding, rectal mass/fistula, vitamin D deficiency, eczema, and hypertriglyceridemia.
Pet. Ex. 1 at 14, 16, 18; Pet. Ex. 3 at 141-49. There were no medical records filed documenting
any reactions following the August 14, 2013 and/or the December 17, 2013 hepatitis B
vaccinations. Petitioner received the third hepatitis B vaccine on May 16, 2014. There were no
medical records filed between May 16, 2014 and February 19, 2015, when petitioner presented
with a cough, sore throat, and left-sided abdominal pain. There was no mention of any events
associated with his hepatitis B vaccinations at that medical visit. Pet. Ex. 3 at 135-37. At his next
medical visit on May 18, 2015, petitioner presented with neck and back pain, which he associated
with the hepatitis B vaccine received one year prior. Id. at 127-30.

Over the next four years, petitioner presented to and received numerous differential and
possible diagnoses from multiple specialists including Drs. Davuluri, Salser, and Gewin (family
medicine), Agnihotri (neurology), Gillford (emergency medicine), Weber, Black, and Wilcox
(gastroenterology), Smith and Chatham (rheumatology), Nozaki (neuromuscular medicine),
McLain (internal medicine), Massey (allergy and immunology), and Lolley and Read
(ophthalmology).

The diagnoses included vitamin B12 and vitamin D deficiency (existing prior to the
vaccinations); pernicious anemia (autoimmune gastritis) due to vitamin B12 deficiency; mild
osteoarthritis and myalgias; somatization or somatoform disorder; possible atrophic gastritis
without bleeding (ruled out on sigmoidoscopy); unspecified iron deficiency anemia; polyarthralgia
and bilateral shoulder pain; suspected (undifferentiated) spondyloarthropathy; possible uveitis
(ruled out); dry eyes or sinus problems; seronegative spondyloarthropathy osteoarthritis of the
cervical spine and knees; right labral tear of the hip; in situ keratomileusis; blepharitis of both eyes,
unspecified eyelid, unspecified type; and keratoconjunctivitis sicca of both eyes. See Pet. Ex. 1 at
39; Pet. Ex. 3 at 7, 11, 19, 41, 46, 51, 62-63, 70; Pet. Ex. 13 at 47, 49, 58; Pet. Ex. 14 at 1; Pet. Ex.
31 at 13, 18; Pet. Ex. 18 at 5; Pet. Ex. 19 at 7-10, 62-63, 114, 118, 137, 141; Pet. Ex. 33 at 4.

Petitioner underwent extensive testing, including but not limited to, MRIs of his cervical
spine with and without contrast on June 11, 2015 showing degenerative changes; an MRI of the
thoracic spine on June 23, 2015, with no cord signal abnormalities appreciated; an MRI of his left
knee on July 6, 2015, which was unremarkable; an MRI of the left shoulder on February 3, 2017
for synovitis/enthesitis, deemed “[e]ssentially unremarkable” and noting that“[n]o abnormality
[was] identified to account for patient’s elbow pain;” an MRI of the hips on April 10, 2018, which
showed a right acetabular labral tear but no evidence of synovitis; an MRI of the thoracic spine on
April 11, 2018, which showed persistent disc protrusion; a negative intrinsic factor antibody test;
a colonoscopy on July 24, 2015 which found hemorrhoids but was otherwise normal; an August
18, 2015 EMG with normal findings; an August 26, 2015 brain MRI with and without contrast,
finding no acute intracranial abnormality; an August 27, 2015 abdominal MRI, showing no
evidence of inflammatory bowel disease or small bowel mass; December 22, 2015 blood work,
which was “unremarkable;” May 31, 2016 blood work, negative for celiac and Hashimoto’s
thyroiditis, with normal TSH, normal antibodies, and normal tissue transglutaminase; a July 26,
2016 x-ray of the left elbow, which was negative; August 19, 2016 blood work with serologic
markers, including sedimentation rate and CRP, which was negative for ANA factor, abnormally

26
low for ferritin, normal for rheumatoid factor, and normal for TSH; October 14, 2016 blood work,
which was unremarkable; August 7, 2017 blood work, which was negative for tissue
transglutaminase but positive for anti-gastric parietal cell antibodies which “may reflect the
presence of atrophic gastritis;” and a January 5, 2018 flexible sigmoidoscopy of colon showing
minimal amounts of chronic inflammation, skin tags, and a healed fistula but no bleeding. See Pet.
Ex. 1 at 25, 27; Pet. Ex. 3 at 24, 29-30, 62-63; Pet. Ex. 12 at 9-18; Pet. Ex. 13 at 46-47, 76; Pet.
Ex. 15 at 4, 6; Pet. Ex. 19 at 10, 62-64, 110, 141-42; Pet. Ex. 31 at 18, 20;

None of petitioner’s medical records mention ankylosing spondylitis as a diagnosis, not
even Dr. Chatham’s office records. “Ankylosing spondylitis” appears for the first time in Dr.
Chatham’s March 8, 2018 letter. Prior to generating this letter, Dr. Chatham had not seen petitioner
for almost a year; his last examination of petitioner was April 25, 2017. Pet. Ex. 19 at 87.
Subsequent to the April 25, 2017 visit, Dr. Chatham sent petitioner an email confirming
petitioner’s diagnosis as seronegative spondyloarthropathy and osteoarthritis of the cervical spine
and knees. Pet. Ex. 14 at 1. However, in his letter dated March 8, 2018, Dr. Chatham wrote that he
treated petitioner “with sulfasalazine and NSAIDs as needed for developing spondyloarthropathy,
which at this time is most consistent with developing ankylosing spondylitis.” Pet. Ex. 17 at 1. A
week later, on March 16, 2018, Dr. Chatham examined petitioner and made no mention of
ankylosing spondylitis or its development in the medical record for that visit. See Pet. Ex. 31 at
11, 13. A little over a month later, Dr. Chatham wrote a second letter dated April 27, 2018, stating
petitioner “continues to be followed at the UAB Rheumatology Clinic for developing ankylosing
spondylitis that presented with seronegative symmetric arthritis, axial pain, [and] stiffness in the
context of HLA-B27 haplotype.” Pet. Ex. 30 at 1. “He presented to our clinic with this complex of
symptoms in 2015 following initiation of immunization with hepatitis B vaccine in 2014. As such,
it is more likely than not that the vaccine triggered the onset of his disease.” Id. Contrary to his
office records, Dr. Chatham again mentioned developing ankylosing spondylitis and added
“seronegative symmetric arthritis,” another diagnosis that is not contained in any medical records.
Id. Notably, Dr. Chatham mentioned hepatitis B vaccinations initiated in 2014 rather than 2013
with the final vaccine administered in May of 2014. Id.

The diagnoses contained in Dr. Chatham’s opinion letters are contradicted by his office
records. On October 12, 2015, Dr. Chatham wrote, “[petitioner] has had numerous serologic as
well as imaging evaluations done in the past year all of which have been unrevealing for any
evidence of acute phase response, autoantibody titer elevations, rheumatoid factor elevation or any
evidence of inflammatory changes referable to his knees.” Pet. Ex. 3 at 42. Additionally, all MRIs
have been unremarkable. Id. at 42-43. “It is possible his arthralgias were accentuated by adjuvants
in the administered HBV vaccine, but theree (sic) is no objective evidence of chronic joint
inflammation presently. Current objective findings on exam and imaging are all easily explained
by evolving osteoarthritis” Id. at 46. He prescribed sulfasalazine. Id. at 47. On January 29, 2016,
Dr. Chatham documented petitioner’s lab results as “unremarkable.” Id. at 19, 24. On April 12,
2016, Dr. Chatham diagnosed osteoarthritis of the neck, knee, and left elbow along with myalgias
and possible uveitis. Id. at 72. On July 26, 2016, Dr. Chatham diagnosed early osteoarthritis signs
observed from the knee exam and probable osteoarthritis of the left elbow. Id. at 76, 79. On January
31, 2017, Dr. Chatham’s impression was cervical, knee, and left elbow osteoarthritis and myalgia.
Pet. Ex. 19 at 118. On April 25, 2017, Dr. Chatham confirmed no sign of uveitis. Id. at 87. In May
7, 2017, Dr. Chatham confirmed his diagnosis in an email to petitioner, “Diagnosis – Right elbow

27
crepitation in 2015. As previously stasted (sic) your diagnosis(sic) are: seronegative
spondyloarthropathy osteoarthritis of the cervical spine, knees.” Pet. Ex. 14 at 1.

The inconsistencies between the diagnoses Dr. Chatham rendered throughout his treatment
of the petitioner and the email he sent to petitioner, when contrasted with the contents of the two
letters he wrote on March 8, 2018 and April 27, 2018, make the diagnoses contained in those letters
unsupportable and unreliable.

Further, petitioner received numerous diagnoses including vitamin B12 deficiency,
vitamin D deficiency, pernicious anemia, and osteoarthritis from multiple physicians. Petitioner
has not been diagnosed with enthesitis or uveitis,62 characteristic of ankylosing spondylitis and in
fact these conditions were ruled out by objective testing. While the records do reflect complaints
of back pain on occasion, the records do not reflect inflammatory back pain or restricted spinal
mobility, also characteristic of the condition. An MRI of petitioner’s hips from 2018 showed no
signs of sacroiliac changes. The only mention of symptoms associated with or characteristic of
ankylosing spondylitis are contained in Dr. Chatham’s April 27, 2018 letter when he wrote
petitioner has inflammatory back pain and seronegative symmetric arthritis despite Dr. Chatham
consistently referring to petitioner as suffering from osteoarthritis, which is very different than
seronegative arthritis,63 in his examination records. Pet. Ex. 30 at 1; Pet. Ex. 13 at 72, 79; Pet. Ex.
19 at 118; Pet. Ex. 14 at 1; Pet. Ex. 31 at 13.

As of August 7, 2017, Dr. Wilcox was unable to link any of petitioner’s complaints to some
specific bowel disease, and, finding anti-gastric parietal cell antibodies to be positive, concluded
the result “may reflect the presence of atrophic gastritis.” Pet. Ex. 19 at 62-64. The diagnosis was
not definitive, and a subsequent sigmoidoscopy showed only mild inflammation. Id. at 7-10.

Petitioner’s most recent records from Dr. Read in 2019 reflect the history petitioner
provided to him of ankylosing spondylitis. However, at the time of the writing of this decision, no
contemporaneous medical records or objective testing have been filed providing any definitive
illness or conditions suffered by petitioner. Petitioner does have pernicious anemia, which has been
related to his vitamin B12 deficiency, and specifically not to his hepatitis B vaccinations by his
treating physicians. See Pet. Ex. 1 at 29, 47; Pet. Ex. 13 at 58.

Dr. Chatham’s contemporaneous medical records, the multitude of tests conducted on
petitioner since May of 2015, the diagnoses and opinions of the physicians of various specialties
who treated or were consulted by petitioner all argue against a diagnosis of ankylosing spondylitis,
seronegative symmetric arthritis, UCTD, autoimmune or atrophic gastritis or any other condition
associated with the hepatitis B vaccinations received by petitioner. Dr. Chatham said it best when
he wrote, “[petitioner] has had numerous serologic as well as imaging evaluations done in the past
year all of which have been unrevealing for any evidence of acute phase response, autoantibody

62
Although petitioner presented for several eye issues and received diagnoses of blepharitis and
keratoconjunctivitis sicca, he was not diagnosed with uveitis. Uveitis is a condition affecting the eyeball
itself, whereas blepharitis and keratoconjunctivitis sicca are conditions affecting the eyelids.
63
Seronegative arthritis occurs when a patient has symptoms of arthritis but does not test positive for
rheumatoid factor. Seronegative, STEDMAN’S at 812110; rheumatoid arthritis (RA), id. at 75730.

28
titer elevations, rheumatoid factor elevation or any evidence of inflammatory changes referable to
his knees.” Pet. Ex. 3 at 42. “It is possible his arthralgias were accentuated by adjuvants in the
administered HBV vaccine, but there is no objective evidence of chronic joint inflammation
presently. Current objective findings on exam and imaging are all easily explained by evolving
osteoarthritis” Id. at 46.

Based on a thorough review of the medical records, I can find no support for any condition
associated with the hepatitis B vaccine and specifically cannot find any support that petitioner was
definitively diagnosed with ankylosing spondylitis, UCTD, or atrophic gastritis/autoimmune
gastritis. Because petitioner has failed to establish a defined and recognized injury, he has failed
to meet his burden to show that the hepatitis B vaccinations significantly aggravated a preexisting
condition. Nevertheless, I will address the requirements for an off-Table significant aggravation
claim.

B. Petitioner’s Theory of Causation

Petitioner filed extensive medical records, medical literature, and two letters from Dr.
Chatham in support of his claim. As set forth above at length and in detail, in his letters, Dr.
Chatham diagnosed petitioner with developing ankylosing spondylitis that has not yet developed
any radiographic footprint characteristic of the disorder and seronegative symmetric arthritis
following initiation with hepatitis B vaccine in 2014 that “more likely than not” triggered the onset
of disease. Pet. Ex. 17 at 1; Pet. Ex. 30 at 1. Dr. Chatham provided nothing more.

Petitioner received hepatitis B vaccines in August 14, 2013, December 17, 2013, and May
16, 2014. There are no medical records filed after any of the vaccinations that document any
complaints, reactions, untoward events or medical visits associated with petitioner’s receipt of any
of hepatitis B vaccinations. Dr. Chatham made note of this in his medical record of January 31,
2017. Pet. Ex. 19 at 115.

Though I have found no support in the record for ankylosing spondylitis, seronegative
symmetric arthritis, UCTD, pernicious anemia, or any other condition alleged by petitioner to be
associated with the hepatitis B vaccinations he received, because Dr. Chatham wrote two opinion
letters in support of petitioner’s claims, an Althen analysis is appropriate.

C. Analysis of Althen and Loving Factors

Typically, “[i]n the absence of a showing of the very existence of any specific injury of
which petitioner complains, the question of causation is not reached.” Lombardi, 656 F.3d at 1353.
However, even if petitioner had shown some definable injury, he would be unable to sustain his
burden of proving causation under the three prongs of Althen or significant aggravation under the
six-factor test established in Loving, in this case. 86 Fed. Cl. at 144.

1. Althen Prong 1/Loving Factor 4: Petitioner Failed to Advance a Medical Theory

Petitioner has failed to offer a reputable medical theory of causation to show that hepatitis
B vaccine can cause or significantly aggravate any of the conditions he alleges that he suffers from.

29
 In his first letter dated March 8, 2018, Dr. Chatham discussed petitioner’s history, claim
that the hepatitis B vaccinations were the cause of his symptoms, and tests that have ruled out
various diagnoses, including developing spondyloarthropathy related to inflammatory bowel
disease, which was not confirmed after an extensive work-up. There were no skin lesions to
implicate developing psoriatic arthritis or gastrointestinal or genitourinary infection to implicate
reactive arthritis. Dr. Chatham then concluded petitioner had recent “developing inflammatory
lower back pain” and was treated with sulfasalazine and NSAIDS for developing
spondyloarthropathy, most consistent with ankylosis spondylitis stating he only had symptoms for
three years, so he had not yet developed any radiographic footprints characteristic of the disorder.
Pet. Ex. 17 at 1. In this letter, Dr. Chatham offered no association between the hepatitis B vaccines
and petitioner’s conditions.

A little over two weeks later, on March 26, 2018, Dr. Chatham examined petitioner for the
first time in 11 months. Petitioner denied ocular complaints and had no new gastrointestinal
complications. Pet. Ex. 31 at 11. Dr. Chatham concluded that petitioner had early osteoarthritic
changes referable to the knee, cervical disease, and probable post-traumatic osteoarthritis of the
left elbow. Id. at 13. There was no mention of inflammatory lower back pain, ankylosing
spondylitis or hepatitis B vaccine related injuries or illness.

One month later, on April 27, 2018, Dr. Chatham generated a second letter, which stated
that petitioner had seronegative symmetric arthritis, axial pain, stiffness, and a positive HLA-B27
after immunization with hepatitis B vaccine in 2014. Pet. Ex. 30 at 1. Dr. Chatham opined that “it
is more likely than not that the vaccine triggered the onset of his disease.” Id.

Dr. Chatham’s letters and records provide no scientific support or sound and reliable theory
for how the hepatitis B vaccines can cause ankylosing spondylitis, seronegative symmetric
arthritis, osteoarthritis, or any other conditions claimed by petitioner.

When evaluating whether petitioners have carried their burden of proof, special masters
consistently reject “conclusory expert statements that are not themselves backed up with reliable
scientific support.” Kreizenbeck v. Sec’y of Health & Human Servs., No. 08-209V, 2018 WL
3679843, at *31 (Fed. Cl. June 22, 2018), review denied, decision aff’d, 141 Fed. Cl. 138 (2018),
aff’d, 945 F.3d 1362 (Fed. Cir. 2020). The undersigned will not rely on “opinion evidence that is
connected to existing data only by the ipse dixit of the expert.” Prokopeas v. Sec’y of Health &
Human Servs., No. 04-1717V, 2019 WL 2509626, at *19 (Fed. Cl. Spec. Mstr. May 24, 2019)
(quoting Moberly ex rel. Moberly v. Sec’y of Health & Human Servs., 85 Fed. Cl. 571, 596 (2009),
aff’d, 592 F.3d 1315 (Fed. Cir. 2010)). Instead, special masters are expected to carefully scrutinize
the reliability of each expert report submitted. See id.

Dr. Chatham’s letters are conclusory in nature and provide no evidence linking petitioner’s
hepatitis B vaccinations to UCTD or ankylosing spondylitis or to any of petitioner’s other co-
morbidities. Dr. Chatham’s conclusion that “it is more likely than not that the vaccine triggered
the onset of his disease,” Pet. Ex. 30 at 1, without any further medical explanation or analysis is
insufficient to provide a sound and reliable medical theory of causation. See R.V. v. Secretary of
Health & Human Services. No. 08-504V, 2016 WL 3882519, at *38-39 (Fed. Cl. Spec. Mstr. Feb.
19, 2016), review denied, decision aff’d, 127 Fed. Cl. 136 (2016).

30
 Further, Dr. Chatham’s letter fails to provide any scientific support or explanation of
whether hepatitis B vaccine can cause any of petitioner’s conditions or specifically, ankylosing
spondylitis or seronegative symmetric arthritis, UCTD, autoimmune gastritis, or atrophic gastritis.
To simply state it is more likely than not that it did, without more, is insufficient to establish
causation. See Garner v. Sec’y of Health & Human Servs., No. 15-63V, 2017 WL 1713184, at *16
(Fed. Cl. Spec. Mstr. Mar. 24, 2017), review denied, decision aff’d, 133 Fed. Cl. 140 (2017)
(providing the petitioner’s expert provided conclusory reasoning for “possible” vaccine causation
is “not sufficient”).

Because Dr. Chatham’s letter is conclusory and provides no “sound and reliable” theory
associating the hepatitis B vaccinations he received with any condition from which he allegedly
suffers or claims to suffer, the undersigned finds petitioner failed to provide preponderant evidence
to support the first prong of Althen and the fourth factor of Loving.

2. Althen Prong 2/Loving Factor 5: Lack of Logical Connection

Even if petitioner had been able to show that the hepatitis B vaccine or vaccines could
cause or significantly aggravate ankylosing spondylitis, seronegative symmetric arthritis, UCTD,
atrophic/autoimmune gastritis, or any of the conditions petitioner reports that he suffers, his
medical records do not support that it did so in this case.

The majority of petitioner’s treating physicians stated that there was no connection between
the hepatitis B vaccine and petitioner’s symptoms. Pet. Ex. 1 at 39; Pet. Ex. 3 at 11, 62-63, 130;
Pet. Ex. 13 at 38, 52-53. Furthermore, petitioner’s treaters suggested alternate causes for his
symptoms; his gastroenterologist, Dr. Weber, concluded that petitioner’s symptoms were more
likely due to pernicious anemia than the hepatitis B vaccine, while others noted that his symptoms
could be explained by his vitamin deficiencies. Pet. Ex. 1 at 44-47; Pet. Ex. 3 at 11, 62-63; Pet.
Ex. 13 at 52-53, 58, 59; Pet. Ex. 15 at 4. These physicians also expressed concerns with petitioner’s
preoccupation with the hepatitis B vaccine and believed that he was suffering from somatization
or a somatic disorder. See Pet. Ex. 3 at 6, 51, 63, 77; Pet. Ex. 13 at 52.

Dr. Chatham stated that, while it was possible petitioner’s arthralgias were temporarily
caused by adjuvants in the vaccine, all objective findings were easily explained by evolving
osteoarthritis. Pet. Ex. 3 at 46. At his January 31, 2017 visit, Dr. Chatham noted no reaction to the
hepatitis B vaccine was ever documented in petitioner’s medical records and his symptoms were
simply due to arthralgia and spondyloarthropathy. Pet. Ex. 19 at 115, 118.

On May 30, 2015, June 2, 2015, June 30, 2015, and August 12, 2015, petitioner’s
neurologist, Dr. Agnihotri, noted normal neurological examination despite petitioner’s reports of
vitamin B12 deficiency, fatigue, joint pain, and transverse myelitis connected to the hepatitis B
vaccine. Pet. Ex. 1 at 60; Pet. Ex. 3 at 102; Pet. Ex. 13 at 32-36, 37-38. Dr. Agnihotri wrote that
petitioner’s symptoms were not related to the hepatitis B vaccine. Pet. Ex. 13 at 38. MRIs of the
cervical and thoracic spine showed degenerative changes. Pet. Ex. 12 at 9-12. An MRI of his left
knee was unremarkable. Id. at 13-14. Dr. Agnihotri documented her concern with petitioner’s
research on hepatitis vaccine and his theories about how his complaints were associated with the
vaccine. She noted somatization and somatoform disorders, along with stress, as possible causes

31
of his symptoms. Pet. Ex. 13 at 52-53; Pet. Ex. 1 at 63. A brain MRI was negative. Pet. Ex. 12 at
15-16. On February 26, 2016, petitioner complained to Dr. Agnihotri of left-sided body pain from
shoulder to upper hip, short term memory loss since the hepatitis B vaccination, now improved,
and concern for “macrophagic myofasciitis” from aluminum adjuvants and myopathy secondary
to hepatitis B vaccination according to the literature. Pet. Ex. 3 at 7-8. Dr. Agnihotri assured
petitioner that the EMG showed no myopathy, there was no need for tissue biopsy, and his vitamin
B12 deficiency could explain his symptoms. The doctor again expressed concern over
somatization or somatoform disorder and suggested counseling, which was refused. Id. at 11.

On July 8, 2015, Drs. Weber and Black, petitioner’s gastroenterologists, noted the history
petitioner provided of ongoing fatigue, subjective weakness in his arms, vitamin B12 deficiency
due to pernicious anemia, and improvement of symptoms with vitamin B12 supplements. Pet. Ex.
13 at 55, 58. Dr. Weber concluded on July 22, 2015, that petitioner’s symptoms were likely due to
pernicious anemia rather than hepatitis B vaccine. Pet. Ex. 1 at 44, 47. An abdominal MRI on
August 27, 2015 ruled out inflammatory bowel disease or mass. Pet. Ex. 12 at 17-18. A
colonoscopy on July 24, 2015 revealed only hemorrhoids. In follow-up on July 29, 2015 and
October 1, 2015, Dr. Weber attributed petitioner’s symptoms to anemia from autoimmune
gastritis/pernicious anemia. Pet. Ex. 1 at 29; Pet. Ex. 3 at 48-49, 51.

On August 12, 2015 and September 8, 2015, petitioner reported to his primary care
physician that his ongoing knee pain “tissue disorder” was connective tissue disease connected to
hepatitis B vaccine. Pet. Ex. 3 at 64. He was again noted to be agitated, anxious, and angry, with
belligerent, compulsive, and abnormal/psychotic thoughts. Id. at 57, 64.

Dr. Smith, a rheumatologist, found no evidence of inflammatory arthritis, but evidence of
osteoarthritis was confirmed by MRI at his July 23, 2015 and August 28, 2015. Pet. Ex. 1 at 34-
35, 39; Pet. Ex. 3 at 70-71, 76. Dr. Smith did not see a connection between hepatitis B vaccine and
osteoarthritis and agreed with Dr. Agnihotri that it was likely somatization. Id. at 40; Pet. Ex. 3 at
77. Petitioner demanded to see the head of the department, Dr. Chatham.

On October 12, 2015, Dr. Chatham wrote “[petitioner] has had numerous serologic as well
as imaging evaluations done in the past year all of which have been unrevealing for any evidence
of acute phase response, autoantibody titer elevations, rheumatoid factor elevation or any evidence
of inflammatory changes referable to his knees.” Additionally, all MRIs have been unremarkable.
Pet. Ex. 3 at 42-43. “It is possible his arthralgias were accentuated by adjuvants in the administered
HBV vaccine, but there is no objective evidence of chronic joint inflammation presently. Current
objective findings on exam and imaging are all easily explained by evolving osteoarthritis” Id. at
46.

Petitioner then reported a need for his aluminum level to be checked as a result of the
adjuvant in the hepatitis B vaccine. Pet. Ex. 3 at 29-30. In March of 2016, petitioner advised that
the left side of his body hurt from all three hepatitis vaccines received in his left arm, demanding
testing and treatment. Dr. Salser advised petitioner that his anxiety was exacerbating his
complaints and suggested a psychiatrist. Id. at 6.

32
 On January 29, 2016, Dr. Chatham wrote “suspected (undifferentiated)
spondyloarthropathy, lab results are unremarkable.” Pet. Ex. 3 at 19, 24. On April 12, 2016, he
documented a diagnosis of osteoarthritis of the neck, knee, and left elbow with myalgias. Pet. Ex.
13 at 72. An elbow x-ray on July 26, 2016 was negative. Dr. Chatham wrote early osteoarthritis
signs observed from knee exam and probably left elbow. Id. at 76, 79. On October 14, 2016, Dr.
Chatham noted bloodwork was unremarkable. Pet. Ex. 19 at 137, 141-42. Dr. Chatham’s
impression on January 31, 2017 remained neck, knee and left elbow osteoarthritis and myalgia. Id.
at 118. An MRI of his left elbow was unremarkable. Id. at 110. On April 25, 2017, Dr. Chatham
noted no signs of uveitis. Id. at 87. On May 7, 2017, Dr. Chatham emailed petitioner with a
diagnosis of seronegative spondyloarthropathy, osteoarthritis of the cervical spine and knees. Pet.
Ex. 14 at 1. Dr. Chatham next saw petitioner on March 26, 2018, at which time he had no ocular
complaints or gastrointestinal complications. Dr. Chatham wrote “early [osteoarthritic] changes
referable to knee by exam, MR; cervical disc disease by cervical radiogrpahs (sic), R; probably
component of post-traumatic [osteoarthritis] of the left elbow.” Pet. Ex. 31 at 11.

In 2016, Dr. Gewin, an internist, was advised by petitioner that he had been diagnosed with
UCTD by Dr. Chatham and by others as well as with atrophic gastritis and vitamin B12 deficiency
associated with hepatitis B vaccine. Bloodwork conducted at that time was normal for TSH,
antibodies, tissue transglutaminase, ANA factor, and rheumatoid factor. Pet. Ex. 15 at 4, 6. His
ferritin level was low. Id. Petitioner advised Dr. Gewin he was administered the hepatitis B
vaccines when he already had painful joints.64 Id. at 5.

Petitioner presented to Dr. Nozaki in August of 2016, reporting myalgias caused by
hepatitis B and advising that he contacted a doctor in France that thinks hepatitis B can cause MS
and myopathy. Pet. Ex. 13 at 84. He was concerned he had macrophagic myofasciitis from
aluminum adjuvants. Id. at 85. Dr. Nozaki found no evidence of myalgias, rashes, or joint swelling.
Id. at 87. Based on the history provided by petitioner, Dr. Nozaki concluded that he may have had
a systemic autoimmune reaction to the vaccine, but an ongoing myopathy was unlikely due to his
normal strength and lack of myalgia. Id. at 88.

Petitioner visited several other doctors, including ophthalmologists, who documented the
history that petitioner provided, but did not diagnose any conditions related to hepatitis B vaccine.
Pet. Ex. 18 at 1, 5; Pet. Ex. 19 at 7-10, 57-62; Pet. Ex. 28 at 1; Pet. Ex. 29 at 2; Pet. Ex. 32 at 1-5;
Pet. Ex. 33 at 1.

The undersigned is compelled to objectively weigh the contemporaneous medical records.
In doing so, the consistent opinions of petitioner’s physicians that his complaints and symptoms
are unrelated to the hepatitis B vaccines he received are more persuasive than two letters written
by Dr. Chatham which are inconsistent with his impressions and contemporaneous medical records
from visits with the petitioner in which he documented his hesitancy in attributing petitioner’s
symptoms to the vaccine. Contemporaneous medical records are assumed to be “complete,” and

64
There were no records filed documenting any complaints of joint pain in 2013 or 2014 prior to or at the
time of his vaccinations; however, if so, petitioner has admitted to the onset of joint pain prior to his
vaccinations. His records do, however, show complaints of abdominal pain, referral to a gastroenterologist
and need for objective testing dating back to 2012, as well as vitamin D deficiency. Pet. Ex. 1 at 8; Pet. Ex.
3 at 140, 143-46.

33
none of petitioner’s other treating physicians provided a causal link between the vaccine and any
of petitioner’s symptoms.

There is insufficient proof to support a logical sequence of cause and effect connecting
petitioner’s alleged development of or significant aggravation of UCTD, ankylosing spondylitis,
seronegative symmetric arthritis, vitamin B12 deficiency, or any other condition to the hepatitis B
vaccinations he received. Accordingly, petitioner has not satisfied the second prong of Althen and
the fifth factor of Loving.

3. Althen Prong 3/Loving Factor 6: No Proximate Temporal Relationship

To satisfy the sixth factor of Loving, which requires petitioner show a proximate temporal
relationship between his hepatitis vaccinations, which he received on August 14, 2013, December
17, 2013, and May 16, 2014, and his alleged symptoms and/or conditions, petitioner would need
to demonstrate an appropriate timeframe for causation or significant aggravation of those
conditions following a hepatitis B vaccine. Since petitioner cannot show that the hepatitis B
vaccine can cause or significantly aggravate any of his claimed conditions, petitioner cannot show
what a reasonable timeframe for the cause or significant aggravation of such conditions following
hepatitis B vaccination would be. Langland v. Sec’y of Health & Human Servs., 109 Fed. Cl. 421,
443 (2013) (“[T]o satisfy the ‘proximate temporal relationship’ prong of the Althen test, petitioners
must demonstrate, by a preponderance of the evidence, that the onset of symptoms occurred within
a time frame for which it is medically acceptable to infer causation-in-fact….With no reputable
theory as to how the vaccination could cause the injury, this exercise is not possible.”) (citing De
Bazan, 539 F.3d at 1352).

The facts and timeframe upon which Dr. Chatham based his opinions were factually
inaccurate and inconsistent with the medical records. In any event, Dr. Chatham’s letters state that
petitioner developed ankylosing spondylitis “after” or “subsequent to” his hepatitis B vaccinations.
As a function of time and place, petitioner certainly received his vaccinations in 2013 and 2014,
and saw Dr. Chatham for the first time in October of 2015, so petitioner’s alleged injuries would
undoubtedly be at some time “after” or “subsequent to” his vaccinations from Dr. Chatham’s
perspective based on the history provided by petitioner. However, Dr. Chatham did not discuss a
medically appropriate timeframe between the receipt of the hepatitis B vaccination(s) and the onset
of ankylosing spondylitis, seronegative symmetric arthritis or any other condition if the hepatitis
B vaccines could or did cause these conditions. Further, petitioner’s medical providers, within their
respective specialties in diagnosing petitioner’s other conditions, specifically discounted his
insistence that any of these medical conditions were related to hepatitis B vaccinations. Moreover,
petitioner had no documented complaints after any of his hepatitis B vaccination. His first reported
complaints that he associated with his August and December 2013 and May of 2014 hepatitis B
vaccinations was reported in May of 2015 as knee pain in June of 2014 and a cold in February of
2015 that lasted too long. Then in June of 2015, he reported a “paralytic attack” with inability to
get out of bed on May 16, 2014. Id. Then on May 27, 2014, he “began to have [an] electric shock
sensation followed by numbness in bilateral hands and arms.” Id. at 121. Petitioner sought no
medical care following these alleged reactions and offered no support for how hepatitis B vaccine
can be temporally associated with any of these events.

34
 Accordingly, petitioner has failed to present preponderant evidence to support the third
prong of Althen and the sixth factor of Loving.

4. Loving Factor 1: Petitioner’s Condition Prior to the Hepatitis B Vaccinations

Prior to petitioner’s receipt of the hepatitis B vaccinations, he suffered from upper
abdominal pain, diarrhea, anal fistula, rectal pain and bleeding, and perianal papillary lesions with
itching. See Pet. Ex. 1 at 18, 20-21, 161, 169, 197; Pet. Ex. 2 at 3-7; Pet. Ex. 3 at 143-46. He
worried about liver disease. Pet. Ex. 1 at 18. He presented to the emergency room for abdominal
pain and rectal bleeding. Id. at 161, 169, 171, 197, 203, 205, 209. He was referred to a
gastroenterologist due to his ongoing issues and a lot of questions. Pet. Ex. 3 at 141. He also
suffered from male pattern hair loss, with erythema, folliculitis, and cutis xerosis of the scalp,
seborrheic dermatitis and vitamin D deficiency. See Pet. Ex. 1 at 14-16; Pet. Ex. 3 at 147-49.

5. Loving Factor 2: Petitioner’s Condition Following the Hepatitis B Vaccinations

At the time that he received his first hepatitis B vaccination on August 14, 2013, petitioner
was noted to have a rectal mass, vitamin D deficiency, eczema, and hypertriglyceridemia, among
other conditions. See Pet. Ex. 3 at 139-41. One week later, petitioner underwent incision and
drainage of a preexisting perianal fistula. See Pet. Ex. 1 at 575-76. The records reflect that
petitioner did not receive any medical care between a post-op follow-up visit on September 5,
2013, and his receipt of the second hepatitis B vaccination on December 17, 2013. See Pet. Ex. 3
at 137-38; Pet. Ex. 1 at 177. The records further reflect that petitioner did not receive any medical
care between his second hepatitis B vaccination and his third hepatitis B vaccination on May 16,
2014. See Pet. Ex. 1 at 176.

Petitioner’s next medical visit was on February 19, 2015, nine months after his third
hepatitis B vaccination, when he presented for cough, sore throat, and left-sided abdominal pain.
See Pet. Ex. 3 at 131-36. On May 18, 2015, approximately one year after his third hepatitis
vaccination, petitioner presented with knee pain in June of 2014. See id. at 126. He also reported
in June of 2015 that he had a paralytic attack and was rendered paralyzed after his May 2014
vaccination but sought no medical care. Pet. Ex. 13 at 24-27.

Thereafter, petitioner spent over four years, presenting to many physicians of varying
specialties, undergoing numerous tests, most of which ruled out diseases and conditions, with few
definitive diagnoses made. He was found to have degenerative changes on MRI of his cervical and
thoracic spine; modest iron deficiency; chronic atrophic gastritis without bleeding; unspecified
iron deficiency anemia; unspecified vitamin D deficiency and possible somatization; anemia due
to hypochlorhydria from autoimmune gastritis and/or pernicious anemia; mild osteoarthritis of the
neck, left knee, and left elbow; hemorrhoids; HLA-B27; vitamin B12 deficiency; low ferritin level;
polyarthralgia and bilateral shoulder pain; suspected undifferentiated spondyloarthropathy;
seronegative spondyloarthropathy; osteoarthritis of the cervical spine and knees; labral tear of the
right hip with no evidence of synovitis; disc protrusion at T1-2 with no focal cord abnormalities;
dry eyes and sinus problems; keratoconjunctivitis sicca and myopia with presbyopia in both eyes;
and blepharitis of both eyes. See Pet. Ex. 1 at 29, 34-35, 39, 44, 47; Pet. Ex. 3 at 11, 19, 41-43, 46-

35
51, 75; Pet. Ex. 12 at 9-12; Pet. Ex. 13 at 72, 79; Pet. Ex. 14; Pet. Ex. 15 at 6; Pet. Ex. 18 at 5; Pet.
Ex. 19 at 114, 137; Pet. Ex. 31 at 18, 20; Pet. Ex. 32 at 4; Pet. Ex. 33 at 4.

As of August 7, 2017, Dr. Wilcox was unable to link any of his complaints to some specific
bowel disease and finding anti-gastric parietal cell antibodies to be positive, concluded the result
“may reflect the presence of atrophic gastritis.” Pet. Ex. 19 at 62-64. The diagnosis was not
definitive, and a subsequent sigmoidoscopy showed only mild inflammation. Id. at 7-10.

6. Loving Factor 3: Petitioner’s Condition Was Not “Significantly Aggravated” by the
Hepatitis B Vaccinations

The statute describes “significant aggravation” as “substantial deterioration” or “markedly
greater” illness or disability, neither of which petitioner experienced following his hepatitis B
vaccinations. See 42 U.S.C. § 300aa-33(4).

Petitioner suffered from gastroenterological and dermatological conditions prior to
receiving the allegedly causal hepatitis B vaccinations; he also had a vitamin D deficiency. Based
on the medical records filed, petitioner did not experience “substantial deterioration” secondary to
any of these conditions after receiving the hepatitis B vaccinations. Beginning nine months after
his third hepatitis B vaccination, petitioner complained of a wide variety of symptoms. In the years
following, he received many diagnoses including vitamin B12 deficiency, possible pernicious
anemia, possible chronic atrophic gastritis, and osteoarthritis of the neck, elbow and knee. None
of these conditions were connected to his hepatitis B vaccinations. The medical records as a whole
fail to support petitioner’s allegation that he experienced “significant deterioration” as a result of
his hepatitis B vaccinations.

IV. Conclusion

The petitioner herein undoubtedly lives with pain in his neck, left elbow and left knee as
well as with many gastrointestinal issues he has had for years. He is certainly convinced the
hepatitis vaccinations he received have caused him to suffer based on his extensive research and
this has caused him a great deal of stress. It is hoped that he finds solace in the results of numerous
objective tests that have ruled out any of the diseases and conditions he has found in the literature
and he fears. To that end, there is no support in the record that petitioner suffers from any disease
or condition causally related to the receipt of hepatitis B vaccinations.

Therefore, upon careful evaluation of all of the evidence submitted in this matter—
including the medical records, Dr. Chatham’s letters, medical literature, submissions by the parties
and affidavit of petitioner—the undersigned concludes that petitioner has not shown by
preponderant evidence that he is entitled to compensation under the Vaccine Act. The petition is
therefore dismissed.

In the absence of a timely filed motion for review (see Appendix B to the Rules of the
Court), the Clerk shall enter judgment in accordance with this decision.65

65
Pursuant to Vaccine Rule 11(a), if a motion for review is not filed within 30 days after the filing of the

36
 IT IS SO ORDERED.

s/ Mindy Michaels Roth
Mindy Michaels Roth
Special Master

special master’s, the clerk will enter judgment immediately.

37